


# Myocardial infarction

**Myocardial infarction (MI)**, also known as a **heart attack**, occurs when blood flow decreases or stops to a part of the heart, causing damage to the heart muscle.<sup>[1]</sup> The most common symptom is chest pain or discomfort which may travel into the shoulder, arm, back, neck or jaw.<sup>[1]</sup> Often it occurs in the center or left side of the chest and lasts for more than a few minutes.<sup>[1]</sup> The discomfort may occasionally feel like heartburn.<sup>[1]</sup> Other symptoms may include shortness of breath, nausea, feeling faint, a cold sweat or feeling tired.<sup>[1]</sup> About 30% of people have atypical symptoms.<sup>[8]</sup> Women more often present without chest pain and instead have neck pain, arm pain or feel tired.<sup>[11]</sup> Among those over 75 years old, about 5% have had an MI with little or no history of symptoms.<sup>[12]</sup> An MI may cause heart failure, an irregular heartbeat, cardiogenic shock or cardiac arrest.<sup>[3][4]</sup>

Most MIs occur due to coronary artery disease.<sup>[3]</sup> Risk factors include high blood pressure, smoking, diabetes, lack of exercise, obesity, high blood cholesterol, poor diet and excessive alcohol intake, among others.<sup>[5][6]</sup> The complete blockage of a coronary artery caused by a rupture of an atherosclerotic plaque is usually the underlying mechanism of an MI.<sup>[3]</sup> MIs are less commonly caused by coronary artery spasms, which may be due to cocaine, significant emotional stress and extreme cold, among others.<sup>[13][14]</sup> A number of tests are useful to help with diagnosis, including electrocardiograms (ECGs), blood tests and coronary angiography.<sup>[7]</sup> An ECG, which is a recording of the heart's electrical activity, may confirm an ST elevation MI (STEMI), if ST elevation is present.<sup>[8][15]</sup> Commonly used blood tests include troponin and less often creatinine kinase MB.<sup>[7]</sup>

Treatment of an MI is time-critical.<sup>[16]</sup> Aspirin is an appropriate immediate treatment for a suspected MI.<sup>[9]</sup> Nitroglycerin or opioids may be used to help with chest pain; however, they do not improve overall

Myocardial infarction	
Other names	Acute myocardial infarction (AMI), heart attack
	
Heart Attack	
A myocardial infarction occurs when an atherosclerotic plaque slowly builds up in the inner lining of a coronary artery and then suddenly ruptures, causing catastrophic thrombus formation, totally occluding the artery and preventing blood flow downstream.	
Specialty	Cardiology, emergency medicine
Symptoms	Chest pain, shortness of breath, nausea, feeling faint, cold sweat, feeling tired; arm, neck, back, jaw, or stomach pain <sup>[1][2]</sup>
Complications	Heart failure, irregular heartbeat, cardiogenic shock, cardiac arrest <sup>[3][4]</sup>
Causes	Usually coronary artery disease <sup>[3]</sup>

outcomes.<sup>[8][9]</sup> Supplemental oxygen is recommended in those with low oxygen levels or shortness of breath.<sup>[9]</sup> In a STEMI, treatments attempt to restore blood flow to the heart and include percutaneous coronary intervention (PCI), where the arteries are pushed open and may be stented, or thrombolysis, where the blockage is removed using medications.<sup>[8]</sup> People who have a non-ST elevation myocardial infarction (NSTEMI) are often managed with the blood thinner heparin, with the additional use of PCI in those at high risk.<sup>[9]</sup> In people with blockages of multiple coronary arteries and diabetes, coronary artery bypass surgery (CABG) may be recommended rather than angioplasty.<sup>[17]</sup> After an MI, lifestyle modifications, along with long term treatment with aspirin, beta blockers and statins, are typically recommended.<sup>[8]</sup>

<b>Risk factors</b>	High blood pressure, smoking, diabetes, lack of exercise, obesity, high blood cholesterol <sup>[5][6]</sup>
<b>Diagnostic method</b>	Electrocardiograms (ECGs), blood tests, coronary angiography <sup>[7]</sup>
<b>Treatment</b>	Percutaneous coronary intervention, thrombolysis <sup>[8]</sup>
<b>Medication</b>	Aspirin, nitroglycerin, heparin <sup>[8][9]</sup>
<b>Prognosis</b>	STEMI 10% risk of death (developed world) <sup>[8]</sup>
<b>Frequency</b>	15.9 million (2015) <sup>[10]</sup>

Worldwide, about 15.9 million myocardial infarctions occurred in 2015.<sup>[10]</sup> More than 3 million people had an ST elevation MI, and more than 4 million had an NSTEMI.<sup>[18]</sup> STEMIs occur about twice as often in men as women.<sup>[19]</sup> About one million people have an MI each year in the United States.<sup>[3]</sup> In the developed world, the risk of death in those who have had an STEMI is about 10%.<sup>[8]</sup> Rates of MI for a given age have decreased globally between 1990 and 2010.<sup>[20]</sup> In 2011, a MI was one of the top five most expensive conditions during inpatient hospitalizations in the US, with a cost of about \$11.5 billion for 612,000 hospital stays.<sup>[21]</sup>

## Contents

---

### Terminology

#### Signs and symptoms

- Pain
- Women
- Other symptoms

#### Causes

- Diet
- Genetics
- Other

#### Mechanism

- Atherosclerosis
- Other causes
- Tissue death

#### Diagnosis

- Criteria
- Types
- Cardiac biomarkers

- Electrocardiogram
- Imaging
- Differential diagnosis

## Management

- Pain
- Anticoagulation
- Angiogram
- Fibrinolysis
- Other
- Rehabilitation

## Prevention

- Primary prevention
- Secondary prevention

## Prognosis

- Complications

## Epidemiology

## Society and culture

- Legal implications

## References

## Further reading

## External links

# Terminology

---

Myocardial infarction (MI) refers to tissue death (infarction) of the heart muscle (myocardium). It is a type of acute coronary syndrome, which describes a sudden or short-term change in symptoms related to blood flow to the heart.<sup>[22]</sup> Unlike other causes of acute coronary syndromes, such as unstable angina, a myocardial infarction occurs when there is cell death, as measured by a blood test for biomarkers (the cardiac protein troponin or the cardiac enzyme CK-MB).<sup>[16]</sup> When there is evidence of an MI, it may be classified as an ST elevation myocardial infarction (STEMI) or Non-ST elevation myocardial infarction (NSTEMI) based on the results of an ECG.<sup>[23]</sup>


The phrase "heart attack" is often used non-specifically to refer to a myocardial infarction and to sudden cardiac death. An MI is different from—but can cause—cardiac arrest, where the heart is not contracting at all or so poorly that all vital organs cease to function, thus causing death. It is also distinct from heart failure, in which the pumping action of the heart is impaired. However, an MI may lead to heart failure.<sup>[24]</sup>

# Signs and symptoms


---

## Pain

Chest pain is the most common symptom of acute myocardial infarction and is often described as a sensation of tightness, pressure, or squeezing. Pain radiates most often to the left arm, but may also radiate to the lower jaw, neck, right arm, back, and upper abdomen.<sup>[25]</sup> The pain most suggestive of an acute MI, with the highest likelihood ratio, is pain radiating to the right arm and shoulder.<sup>[26]</sup> Similarly, chest pain similar to a previous heart attack is also suggestive.<sup>[27]</sup> The pain associated with MI is usually diffuse, does not change with position, and lasts for more than 20 minutes.<sup>[23]</sup> Levine's sign, in which a person localizes the chest pain by clenching one or both fists over their sternum, has classically been thought to be predictive of cardiac chest pain, although a prospective observational study showed it had a poor positive predictive value.<sup>[28]</sup> Pain that responds to nitroglycerin does not indicate the presence or absence of a myocardial infarction.<sup>[9]</sup>



## Women



Range of myocardial infarction symptoms in women



Areas where pain is experienced in myocardial infarction, showing common (dark red) and less common (light red) areas on the chest and back.

In women, myocardial infarctions can present with different symptoms. The classic presentation of chest pain occurs in about 50% of women. Women can also commonly experience back or neck pain, indigestion, heartburn, lightheadedness, shortness of breath, fatigue, nausea, or pain in the back of the jaw. These symptoms are often overlooked or mistaken for another condition.<sup>[29][30]</sup>

## Other symptoms

Chest pain may be accompanied by sweating, nausea or vomiting, and fainting,<sup>[23][26]</sup> and these symptoms may also occur without any pain at all.<sup>[25]</sup> In women, the most common symptoms of myocardial infarction include shortness of breath, weakness, and fatigue.<sup>[31]</sup> Shortness of breath is a common, and sometimes the only symptom, occurring when damage to the heart limits the output of the left ventricle, with breathlessness arising either from low oxygen in the blood, or pulmonary

edema.<sup>[25][32]</sup> Other less common symptoms include weakness, light-headedness, palpitations, and abnormalities in heart rate or blood pressure.<sup>[16]</sup> These symptoms are likely induced by a massive surge of catecholamines from the sympathetic nervous system, which occurs in response to pain and, where present, low blood pressure.<sup>[33]</sup> Loss of consciousness due to inadequate blood flow to the brain and cardiogenic shock, and sudden death, frequently due to the development of ventricular fibrillation, can occur in myocardial infarctions.<sup>[24]</sup> Cardiac arrest, and atypical symptoms such as palpitations, occur more frequently in women, the elderly, those with diabetes, in people who have just had surgery, and in critically ill patients.<sup>[23]</sup>

"Silent" myocardial infarctions can happen without any symptoms at all.<sup>[12]</sup> These cases can be discovered later on electrocardiograms, using blood enzyme tests, or at autopsy after a person has died. Such silent myocardial infarctions represent between 22 and 64% of all infarctions,<sup>[12]</sup> and are more common in the elderly,<sup>[12]</sup> in those with diabetes mellitus<sup>[16]</sup> and after heart transplantation. In people with diabetes, differences in pain threshold, autonomic neuropathy, and psychological factors have been cited as possible explanations for the lack of symptoms.<sup>[34]</sup> In heart transplantation, the donor heart is not fully innervated by the nervous system of the recipient.<sup>[35]</sup>

## Causes

---

The most prominent risk factors for myocardial infarction are older age, actively smoking, high blood pressure, diabetes mellitus, and total cholesterol and high-density lipoprotein levels.<sup>[19]</sup> Many risk factors of myocardial infarction are shared with coronary artery disease, the primary cause of myocardial infarction,<sup>[16]</sup> with other risk factors including male sex, low levels of physical activity, a past family history, obesity, and alcohol use.<sup>[16]</sup> Risk factors for myocardial disease are often included in risk factor stratification scores, such as the Framingham Risk Score.<sup>[19]</sup> At any given age, men are more at risk than women for the development of cardiovascular disease.<sup>[36]</sup> High levels of blood cholesterol is a known risk factor, particularly high low-density lipoprotein, low high-density lipoprotein, and high triglycerides.<sup>[37]</sup>

Many risk factors for myocardial infarction are potentially modifiable, with the most important being tobacco smoking (including secondhand smoke).<sup>[16]</sup> Smoking appears to be the cause of about 36% and obesity the cause of 20% of coronary artery disease.<sup>[38]</sup> Lack of physical activity has been linked to 7–12% of cases.<sup>[38][39]</sup> Less common causes include stress-related causes such as job stress, which accounts for about 3% of cases,<sup>[38]</sup> and chronic high stress levels.<sup>[40]</sup>

## Diet

There is varying evidence about the importance of saturated fat in the development of myocardial infarctions. Eating polyunsaturated fat instead of saturated fats has been shown in studies to be associated with a decreased risk of myocardial infarction,<sup>[41]</sup> while other studies find little evidence that reducing dietary saturated fat or increasing polyunsaturated fat intake affects heart attack risk.<sup>[42][43]</sup> Dietary cholesterol does not appear to have a significant effect on blood cholesterol and thus recommendations about its consumption may not be needed.<sup>[44]</sup> Trans fats do appear to increase risk.<sup>[42]</sup> Acute and prolonged intake of high quantities of alcoholic drinks (3–4 or more daily) increases the risk of a heart attack.<sup>[45]</sup>

## Genetics

Family history of ischemic heart disease or MI, particularly if one has a male first-degree relative (father, brother) who had a myocardial infarction before age 55 years, or a female first-degree relative (mother, sister) less than age 65 increases a person's risk of MI.<sup>[36]</sup>

Genome-wide association studies have found 27 genetic variants that are associated with an increased risk of myocardial infarction.<sup>[46]</sup> The strongest association of MI has been found with chromosome 9 on the short arm *p* at locus 21, which contains genes CDKN2A and 2B, although the single nucleotide polymorphisms that are implicated are within a non-coding region.<sup>[46]</sup> The majority of these variants are in regions that have not been previously implicated in coronary artery disease. The following genes have an association with MI: PCSK9, SORT1, MIA3, WDR12, MRAS, PHACTR1, LPA, TCF21, MTHFDSL, ZC3HC1, CDKN2A, 2B, ABO, PDGF0, APOA5, MNF1ASM283, COL4A1, HHIPC1, SMAD3, ADAMTS7, RAS1, SMG6, SNF8, LDLR, SLC5A3, MRPS6, KCNE2.<sup>[46]</sup>

## Other

The risk of having a myocardial infarction increases with older age, low physical activity, and low socioeconomic status.<sup>[36]</sup> Heart attacks appear to occur more commonly in the morning hours, especially between 6AM and noon.<sup>[47]</sup> Evidence suggests that heart attacks are at least three times more likely to occur in the morning than in the late evening.<sup>[48]</sup> Shift work is also associated with a higher risk of MI.<sup>[49]</sup> And one analysis has found an increase in heart attacks immediately following the start of daylight saving time.<sup>[50]</sup>

Women who use combined oral contraceptive pills have a modestly increased risk of myocardial infarction, especially in the presence of other risk factors.<sup>[51]</sup> The use of non-steroidal anti inflammatory drugs (NSAIDs), even for as short as a week, increases risk.<sup>[52]</sup>

Endometriosis in women under the age of 40 is an identified risk factor.<sup>[53]</sup>

Air pollution is also an important modifiable risk. Short-term exposure to air pollution such as carbon monoxide, nitrogen dioxide, and sulfur dioxide (but not ozone) have been associated with MI and other acute cardiovascular events.<sup>[54]</sup> For sudden cardiac deaths, every increment of 30 units in Pollutant Standards Index correlated with an 8% increased risk of out-of-hospital cardiac arrest on the day of exposure.<sup>[55]</sup> Extremes of temperature are also associated.<sup>[56]</sup>

A number of acute and chronic infections including *Chlamydomphila pneumoniae*, influenza, *Helicobacter pylori*, and *Porphyromonas gingivalis* among others have been linked to atherosclerosis and myocardial infarction.<sup>[57]</sup> As of 2013, there is no evidence of benefit from antibiotics or vaccination, however, calling the association into question.<sup>[57][58]</sup> Myocardial infarction can also occur as a late consequence of Kawasaki disease.<sup>[59]</sup>

Calcium deposits in the coronary arteries can be detected with CT scans. Calcium seen in coronary arteries can provide predictive information beyond that of classical risk factors.<sup>[60]</sup> High blood levels of the amino acid homocysteine is associated with premature atherosclerosis;<sup>[61]</sup> whether elevated homocysteine in the normal range is causal is controversial.<sup>[62]</sup>

In people without evident coronary artery disease, possible causes for the myocardial infarction are coronary spasm or coronary artery dissection.<sup>[63]</sup>


## Mechanism

---

## Atherosclerosis

The most common cause of a myocardial infarction is the rupture of an atherosclerotic plaque on an artery supplying heart muscle.<sup>[24][64]</sup> Plaques can become unstable, rupture, and additionally promote the formation of a blood clot that blocks the artery; this can occur in minutes. Blockage of an artery can lead to tissue death in tissue being supplied by that artery.<sup>[65]</sup> Atherosclerotic plaques are often present for decades before they result in symptoms.<sup>[65]</sup>

The gradual buildup of cholesterol and fibrous tissue in plaques in the wall of the coronary arteries or other arteries, typically over decades, is termed atherosclerosis.<sup>[66]</sup> Atherosclerosis is characterized by progressive inflammation of the walls of the arteries.<sup>[65]</sup> Inflammatory cells, particularly macrophages, move into affected arterial walls. Over time, they become laden with cholesterol products, particularly LDL, and become foam cells. A cholesterol core forms as foam cells die. In response to growth factors secreted by macrophages, smooth muscle and other cells move into the plaque and act to stabilize it. A stable plaque may have a thick fibrous cap with calcification. If there is ongoing inflammation, the cap may be thin or ulcerate. Exposed to the pressure associated with blood flow, plaques, especially those with a thin lining, may rupture and trigger the formation of a blood clot (thrombus).<sup>[65]</sup> The cholesterol crystals have been associated with plaque rupture through mechanical injury and inflammation.<sup>[67]</sup>



Play media

The animation shows plaque buildup or a coronary artery spasm can lead to a heart attack and how blocked blood flow in a coronary artery can lead to a heart attack.

## Other causes

Atherosclerotic disease is not the only cause of myocardial infarction, and it may exacerbate or contribute to other causes. A myocardial infarction may result from a heart with a limited blood supply subject to increased oxygen demands, such as in fever, a fast heart rate, hyperthyroidism, too few red blood cells in the bloodstream, or low blood pressure. Damage or failure of procedures such as percutaneous coronary intervention or coronary artery bypass grafts may cause a myocardial infarction. Spasm of coronary arteries, such as Prinzmetal's angina may cause blockage.<sup>[23][25]</sup>

## Tissue death

If impaired blood flow to the heart lasts long enough, it triggers a process called the ischemic cascade; the heart cells in the territory of the blocked coronary artery die (infarction), chiefly through necrosis, and do not grow back. A collagen scar forms in their place.<sup>[65]</sup> When an artery is blocked, cells lack oxygen, needed to produce ATP in mitochondria. ATP is required for the maintenance of electrolyte balance, particularly through the Na/K ATPase. This leads to an ischemic cascade of intracellular changes, necrosis and apoptosis of affected cells.<sup>[68]</sup>

Cells in the area with the worst blood supply, just below the inner surface of the heart (endocardium), are most susceptible to damage.<sup>[69]</sup> Ischemia first affects this region, the subendocardial region, and tissue begins to die within 15–30 minutes of loss of blood supply.<sup>[70]</sup> The dead tissue is surrounded by a zone



of potentially reversible ischemia that progresses to become a full-thickness *transmural* infarct.<sup>[68][70]</sup> The initial "wave" of infarction can take place over 3–4 hours.<sup>[65][68]</sup> These changes are seen on gross pathology and cannot be predicted by the presence or absence of Q waves on an ECG.<sup>[69]</sup> The position, size and extent of an infarct depends on the affected artery, totality of the blockage, duration of the blockage, the presence of collateral blood vessels, oxygen demand, and success of interventional procedures.<sup>[25][64]</sup>



Drawing of the heart showing anterior left ventricle wall infarction

Tissue death and myocardial scarring alter the normal conduction pathways of the heart, and weaken affected areas. The size and location puts a person at risk of abnormal heart rhythms (arrhythmias) or heart block, aneurysm of the heart ventricles, inflammation of the heart wall following infarction, and rupture of the heart wall that can have catastrophic consequences.<sup>[64][71]</sup>

## Diagnosis

### Criteria

An acute myocardial infarction, according to current consensus, is defined by elevated cardiac biomarkers with a rising or falling trend and at least one of the following:<sup>[23][72]</sup>

- Symptoms relating to ischemia
- Changes on an electrocardiogram (ECG), such as ST segment changes, new left bundle branch block, or Q waves
- Changes in the motion of the heart wall on imaging
- Demonstration of a thrombus on angiogram or at autopsy.




Diagram showing the blood supply to the heart by the two major blood vessels, the left and right coronary arteries (labelled LCA and RCA). A myocardial infarction (2) has occurred with blockage of a branch of the left coronary artery (1).

### Types

Myocardial infarctions are generally clinically classified into ST elevation MI (STEMI) and non-ST elevation MI (NSTEMI). These are based on changes to an ECG.<sup>[23]</sup> STEMIs make up about 25 – 40% of myocardial infarctions.<sup>[19]</sup> A more explicit classification system, based on international consensus in 2012, also exists. This classifies myocardial infarctions into five types:<sup>[23]</sup>

1. Spontaneous MI related to plaque erosion and/or rupture, fissuring, or dissection
2. MI related to ischemia, such as from increased oxygen demand or decreased supply, e.g. coronary artery spasm, coronary embolism, anemia, arrhythmias, high blood pressure or low blood pressure
3. Sudden unexpected cardiac death, including cardiac arrest, where symptoms may suggest MI, an ECG may be taken with suggestive changes, or a blood clot is found in a coronary



artery by angiography and/or at autopsy, but where blood samples could not be obtained, or at a time before the appearance of cardiac biomarkers in the blood

4. Associated with coronary angioplasty or stents

- Associated with percutaneous coronary intervention (PCI)
- Associated with stent thrombosis as documented by angiography or at autopsy

5. Associated with CABG

6. Associated with spontaneous coronary artery dissection in young, fit women

## Cardiac biomarkers

There are a number of different biomarkers used to determine the presence of cardiac muscle damage. Troponins, measured through a blood test, are considered to be the best,<sup>[19]</sup> and are preferred because they have greater sensitivity and specificity for measuring injury to the heart muscle than other tests.<sup>[64]</sup> A rise in troponin occurs within 2–3 hours of injury to the heart muscle, and peaks within 1–2 days. The level of the troponin, as well as a change over time, are useful in measuring and diagnosing or excluding myocardial infarctions, and the diagnostic accuracy of troponin testing is improving over time.<sup>[64]</sup> One high-sensitivity cardiac troponin is able to rule out a heart attack as long as the ECG is normal.<sup>[73][74]</sup>


Other tests, such as CK-MB or myoglobin, are discouraged.<sup>[75]</sup> CK-MB is not as specific as troponins for acute myocardial injury, and may be elevated with past cardiac surgery, inflammation or electrical cardioversion; it rises within 4–8 hours and returns to normal within 2–3 days.<sup>[25]</sup> Copeptin may be useful to rule out MI rapidly when used along with troponin.<sup>[76]</sup>

## Electrocardiogram

Electrocardiograms (ECGs) are a series of leads placed on a person's chest that measure electrical activity associated with contraction of heart muscle.<sup>[77]</sup> The taking of an ECG is an important part in the workup of an AMI,<sup>[23]</sup> and ECGs are often not just taken once, but may be repeated over minutes to hours, or in response to changes in signs or symptoms.<sup>[23]</sup>

ECG readouts produce a waveform with different labelled features.<sup>[77]</sup> In addition to a rise in biomarkers, a rise in the ST segment,

changes in the shape or flipping of T waves, new Q waves, or a new left bundle branch block can be used to diagnose an AMI.<sup>[23]</sup> In addition, ST elevation can be used to diagnose an ST segment myocardial infarction (STEMI). A rise must be new in V2 and V3  $\geq 2$  mm (0.2 mV) for males or  $\geq 1.5$  mm (0.15 mV) for females or  $\geq 1$  mm (0.1 mV) in two other adjacent chest or limb leads.<sup>[19][23]</sup> ST elevation is associated with infarction, and may be preceded by changes indicating ischemia, such as ST depression or inversion of the T waves.<sup>[77]</sup> Abnormalities can help differentiate the location of an infarct, based on the leads that are affected by changes.<sup>[16]</sup> Early STEMIs may be preceded by peaked T waves.<sup>[19]</sup> Other ECG abnormalities relating to complications of acute myocardial infarctions may also be evident, such as atrial or ventricular fibrillation.<sup>[78]</sup>




A 12-lead ECG showing a STEMI. Elevation of the ST segment can be seen in some leads.

## Imaging

Noninvasive imaging plays an important role in the diagnosis and characterisation of myocardial infarction.<sup>[23]</sup> Tests such as chest X-rays can be used to explore and exclude alternate causes of a person's symptoms.<sup>[23]</sup> Tests such as stress echocardiography and myocardial perfusion imaging can confirm a diagnosis when a person's history, physical examination (including cardiac examination) ECG, and cardiac biomarkers suggest the likelihood of a problem.<sup>[79]</sup>

Echocardiography, an ultrasound scan of the heart, is able to visualize the heart, its size, shape, and any abnormal motion of the heart walls as they beat that may indicate a myocardial infarction. The flow of blood can be imaged, and contrast dyes may be given to improve image.<sup>[23]</sup> Other scans using radioactive contrast include SPECT CT-scans using thallium, sestamibi (MIBI scans) or tetrofosmin; or a PET scan using Fludeoxyglucose or rubidium-82.<sup>[23]</sup> These nuclear medicine scans can visualize the perfusion of heart muscle.<sup>[23]</sup> SPECT may also be used to determine viability of tissue, and whether areas of ischemia are inducible.<sup>[23][80]</sup>

Medical societies and professional guidelines recommend that the physician confirm a person is at high risk for myocardial infarction before conducting imaging tests to make a diagnosis,<sup>[79][81]</sup> as such tests are unlikely to change management and result in increased costs.<sup>[79]</sup> Patients who have a normal ECG and who are able to exercise, for example, do not merit routine imaging.<sup>[79]</sup>



Poor movement of the heart due to an MI as seen on ultrasound<sup>[82]</sup>      Pulmonary edema due to an MI as seen on ultrasound<sup>[82]</sup>

## Differential diagnosis

There are many causes of chest pain, which can originate from the heart, lungs, gastrointestinal tract, aorta, and other muscles, bones and nerves surrounding the chest.<sup>[83]</sup> In addition to myocardial infarction, other causes include angina, insufficient blood supply (ischemia) to the heart muscles without evidence of cell death, gastroesophageal reflux disease; pulmonary embolism, tumors of the lungs, pneumonia, rib fracture, costochondritis, heart failure and other musculoskeletal injuries.<sup>[83][23]</sup> Rarer severe differential diagnoses include aortic dissection, esophageal rupture, tension pneumothorax, and pericardial effusion causing cardiac tamponade.<sup>[84]</sup> The chest pain in an MI may mimic heartburn.<sup>[24]</sup> Causes of sudden-onset breathlessness generally involve the lungs or heart – including pulmonary

edema, pneumonia, allergic reactions and asthma, and pulmonary embolus, acute respiratory distress syndrome and metabolic acidosis.<sup>[83]</sup> There are many different causes of fatigue, and myocardial infarction is not a common cause.<sup>[85]</sup>

## Management

---

A myocardial infarction requires immediate medical attention. Treatment aims to preserve as much heart muscle as possible, and to prevent further complications.<sup>[25]</sup> Treatment depends on whether the myocardial infarction is a STEMI or NSTEMI.<sup>[64]</sup> Treatment in general aims to unblock blood vessels, reduce blood clot enlargement, reduce ischemia, and modify risk factors with the aim of preventing future MIs.<sup>[25]</sup> In addition, the main treatment for myocardial infarctions with ECG evidence of ST elevation (STEMI) include thrombolysis or percutaneous coronary intervention, although PCI is also ideally conducted within 1–3 days for NSTEMI.<sup>[64]</sup> In addition to clinical judgement, risk stratification may be used to guide treatment, such as with the TIMI and GRACE scoring systems.<sup>[16][64][86]</sup>

## Pain

The pain associated with myocardial infarction may be treated with nitroglycerin or morphine.<sup>[25]</sup> Nitroglycerin (given under the tongue or intravenously) may improve the blood supply to the heart, and decrease the work the heart must do.<sup>[25]</sup> It is an important part of therapy for its pain relief, despite there being no benefit to overall mortality.<sup>[25][87]</sup> Morphine may also be used, and is effective for the pain associated with STEMI.<sup>[25]</sup> The evidence for benefit from morphine on overall outcomes, however, is poor and there is some evidence of potential harm.<sup>[88][89]</sup>

## Anticoagulation

Aspirin, an antiplatelet anticoagulant, is given as a loading dose with the goal of reducing the clot size and reduce further clotting in the affected artery.<sup>[25][64]</sup> It is known to decrease mortality associated with acute myocardial infarction by at least 50%.<sup>[64]</sup> P2Y12 inhibitors such as clopidogrel, prasugrel and ticagrelor are given concurrently, also as a loading dose, with the dose depending on whether further surgical management or fibrinolysis is planned.<sup>[64]</sup> Prasugrel and ticagrelor are recommended in European and American guidelines, as they are active more quickly and consistently than clopidogrel.<sup>[64]</sup> P2Y12 inhibitors are recommended in both NSTEMI and STEMI, including in PCI, with evidence also to suggest improved mortality.<sup>[64]</sup> Heparins, particularly in the unfractionated form, act at several points in the clotting cascade, help to prevent the enlargement of a clot, and are also given in myocardial infarction, owing to evidence suggesting improved mortality rates.<sup>[64]</sup> In very high-risk scenarios, inhibitors of the platelet glycoprotein  $\alpha_{IIb}\beta_{3a}$  receptor such as eptifibatide or tirofiban may be used.<sup>[64]</sup>

There is varying evidence on the mortality benefits in NSTEMI. A 2014 review of P2Y12 inhibitors such as clopidogrel found they do not change the risk of death when given to people with a suspected NSTEMI prior to PCI,<sup>[90]</sup> nor do heparins change the risk of death.<sup>[91]</sup> They do decrease the risk of having a further myocardial infarction.<sup>[64][91]</sup>

## Angiogram

Primary percutaneous coronary intervention (PCI) is the treatment of choice for STEMI if it can be performed in a timely manner, ideally within 90–120 minutes of contact with a medical provider.<sup>[64][92]</sup> Some recommend it is also done in NSTEMI within 1–3 days, particularly when considered high-risk.<sup>[64]</sup>

A 2017 review, however, did not find a difference between early versus later PCI in NSTEMI.<sup>[93]</sup>

PCI involves small probes, inserted through peripheral blood vessels such as the femoral artery or radial artery into the blood vessels of the heart. The probes are then used to identify and clear blockages using small balloons, which are dragged through the blocked segment, dragging away the clot, or the insertion of stents.<sup>[25][64]</sup> Coronary artery bypass grafting is only considered when the affected area of heart muscle large, and PCI is unsuitable, for example with difficult cardiac anatomy.<sup>[94]</sup> After PCI, people are generally placed on aspirin indefinitely and on dual antiplatelet therapy (generally aspirin and clopidogrel) for at least a year.<sup>[19][64][95]</sup>

## Fibrinolysis

If PCI cannot be performed within 90 to 120 minutes in STEMI then fibrinolysis, preferably within 30 minutes of arrival to hospital, is recommended.<sup>[64][96]</sup> If a person has had symptoms for 12 to 24 hours evidence for effectiveness of thrombolysis is less and if they have had symptoms for more than 24 hours it is not recommended.<sup>[97]</sup> Thrombolysis involves the administration of medication that activates the enzymes that normally dissolve blood clots. These medications include tissue plasminogen activator, reteplase, streptokinase, and tenecteplase.<sup>[25]</sup> Thrombolysis is not recommended in a number of situations, particularly when associated with a high risk of bleeding or the potential for problematic bleeding, such as active bleeding, past strokes or bleeds into the brain, or severe hypertension. Situations in which thrombolysis may be considered, but with caution, include recent surgery, use of anticoagulants, pregnancy, and proclivity to bleeding.<sup>[25]</sup> Major risks of thrombolysis are major bleeding and intracranial bleeding.<sup>[25]</sup> Pre-hospital thrombolysis reduces time to thrombolytic treatment, based on studies conducted in higher income countries, however it is unclear whether this has an impact on mortality rates.<sup>[98]</sup>

## Other

In the past, high flow oxygen was recommended for everyone with a possible myocardial infarction.<sup>[75]</sup> More recently, no evidence was found for routine use in those with normal oxygen levels and there is potential harm from the intervention.<sup>[99][100][101][102]</sup> Therefore, oxygen is currently only recommended if oxygen levels are found to be low or if someone is in respiratory distress.<sup>[25][75]</sup>

If despite thrombolysis there is significant cardiogenic shock, continued severe chest pain, or less than a 50% improvement in ST elevation on the ECG recording after 90 minutes, then rescue PCI is indicated emergently.<sup>[103][104]</sup>

Those who have had cardiac arrest may benefit from targeted temperature management with evaluation for implementation of hypothermia protocols. Furthermore, those with cardiac arrest, and ST elevation at any time, should usually have angiography.<sup>[19]</sup> Aldosterone antagonists appear to be useful in people who have had an STEMI and do not have heart failure.<sup>[105]</sup>

## Rehabilitation

Cardiac rehabilitation benefits many who have experienced myocardial infarction,<sup>[64]</sup> even if there has been substantial heart damage and resultant left ventricular failure. It should start soon after discharge from the hospital. The program may include lifestyle advice, exercise, social support, as well as

recommendations about driving, flying, sport participation, stress management, and sexual intercourse.<sup>[106]</sup>

## Prevention

---

There is a large crossover between the lifestyle and activity recommendations to prevent a myocardial infarction, and those that may be adopted as secondary prevention after an initial myocardial infarction,<sup>[64]</sup> because of shared risk factors and an aim to reduce atherosclerosis affecting heart vessels.<sup>[25]</sup>

### Primary prevention

#### Lifestyle

Physical activity can reduce the risk of cardiovascular disease, and people at risk are advised to engage in 150 minutes of moderate or 75 minutes of vigorous intensity aerobic exercise a week.<sup>[107]</sup> Keeping a healthy weight, drinking alcohol within the recommended limits, and quitting smoking reduce the risk of cardiovascular disease.<sup>[107]</sup>

Substituting polyunsaturated fats such as olive oil and rapeseed oil instead of saturated fats may reduce the risk of myocardial infarction,<sup>[41]</sup> although there is not universal agreement.<sup>[42]</sup> Dietary modifications are recommended by some national authorities, with recommendations including increasing the intake of wholegrain starch, reducing sugar intake (particularly of refined sugar), consuming five portions of fruit and vegetables daily, consuming two or more portions of fish per week, and consuming 4–5 portions of unsalted nuts, seeds, or legumes per week.<sup>[107]</sup> The dietary pattern with the greatest support is the Mediterranean diet.<sup>[108]</sup> Vitamins and mineral supplements are of no proven benefit,<sup>[109]</sup> and neither are plant stanols or sterols.<sup>[107]</sup>

Public health measures may also act at a population level to reduce the risk of myocardial infarction, for example by reduce unhealthy diets (excessive salt, saturated fat and trans fat) including food labeling and marketing requirements as well as requirements for catering and restaurants, and stimulating physical activity. This may be part of regional cardiovascular disease prevention programs, or through the health impact assessment of regional and local plans and policies.<sup>[110]</sup>

Most guidelines recommend combining different preventive strategies. A 2015 Cochrane Review found some evidence that such an approach might help with blood pressure, body mass index and waist circumference. However, there was insufficient evidence to show an effect on mortality or actual cardiovascular events.<sup>[111]</sup>

#### Medication

Statins, drugs that act to lower blood cholesterol, decrease the incidence and mortality rates of myocardial infarctions.<sup>[112]</sup> They are often recommended in those at an elevated risk of cardiovascular diseases.<sup>[107]</sup>

Aspirin has been studied extensively in people considered at increased risk of myocardial infarction. Based on numerous studies in different groups (e.g. people with or without diabetes), there does not appear to be a benefit strong enough to outweigh the risk of excessive bleeding.<sup>[113][114]</sup> Nevertheless,

many clinical practice guidelines continue to recommend aspirin for primary prevention,<sup>[115]</sup> and some researchers feel that those with very high cardiovascular risk but low risk of bleeding should continue to receive aspirin.<sup>[116]</sup>

## Secondary prevention

There is a large crossover between the lifestyle and activity recommendations to prevent a myocardial infarction, and those that may be adopted as secondary prevention after an initial myocardial infarct.<sup>[64]</sup> Recommendations include stopping smoking, a gradual return to exercise, eating a healthy diet, low in saturated fat and low in cholesterol, and drinking alcohol within recommended limits, exercising, and trying to achieve a healthy weight.<sup>[64][106]</sup> Exercise is both safe and effective even if people have had stents or heart failure,<sup>[117]</sup> and is recommended to start gradually after 1–2 weeks.<sup>[64]</sup> Counselling should be provided relating to medications used, and for warning signs of depression.<sup>[64]</sup> Previous studies suggested a benefit from omega-3 fatty acid supplementation but this has not been confirmed.<sup>[106]</sup>

## Medications

Following a heart attack, nitrates, when taken for two days, and ACE-inhibitors decrease the risk of death.<sup>[118]</sup> Other medications include:

Aspirin is continued indefinitely, as well as another antiplatelet agent such as clopidogrel or ticagrelor ("dual antiplatelet therapy" or DAPT) for up to twelve months.<sup>[106]</sup> If someone has another medical condition that requires anticoagulation (e.g. with warfarin) this may need to be adjusted based on risk of further cardiac events as well as bleeding risk.<sup>[106]</sup> In those who have had a stent, more than 12 months of clopidogrel plus aspirin does not affect the risk of death.<sup>[119]</sup>

Beta blocker therapy such as metoprolol or carvedilol is recommended to be started within 24 hours, provided there is no acute heart failure or heart block.<sup>[19][75]</sup> The dose should be increased to the highest tolerated.<sup>[106]</sup> Contrary to what was long believed, the use of beta blockers does not appear to affect the risk of death, possibly because other treatments for MI have improved.<sup>[120]</sup> When beta blocker medication is given within the first 24–72 hours of a STEMI no lives are saved. However, 1 in 200 people were prevented from a repeat heart attack, and another 1 in 200 from having an abnormal heart rhythm. Additionally, for 1 in 91 the medication causes a temporary decrease in the heart's ability to pump blood.<sup>[121]</sup>

ACE inhibitor therapy should be started within 24 hours, and continued indefinitely at the highest tolerated dose. This is provided there is no evidence of worsening kidney failure, high potassium, low blood pressure, or known narrowing of the renal arteries.<sup>[64]</sup> Those who cannot tolerate ACE inhibitors may be treated with an angiotensin II receptor antagonist.<sup>[106]</sup>

Statin therapy has been shown to reduce mortality and subsequent cardiac events, and should be commenced with the aim of lowering LDL cholesterol. Other medications, such as ezetimibe, may also be added with this goal in mind.<sup>[64]</sup>

Aldosterone antagonists (spironolactone or eplerenone) may be used if there is evidence of left ventricular dysfunction after an MI, ideally after beginning treatment with an ACE inhibitor.<sup>[106][122]</sup>

## Other



A defibrillator, an electric device connected to the heart and surgically inserted under the skin, may be recommended. This is particularly if there are any ongoing signs of heart failure, with a low left ventricular ejection fraction and a New York Heart Association grade II or III after 40 days of the infarction.<sup>[64]</sup> Defibrillators detect potentially fatal arrhythmia and deliver an electrical shock to the person to depolarize a critical mass of the heart muscle.<sup>[123]</sup>

## Prognosis

---

The prognosis after myocardial infarction varies greatly depending on the extent and location of the affected heart muscle, and the development and management of complications.<sup>[16]</sup> Prognosis is worse with older age, and social isolation.<sup>[16]</sup> Anterior infarcts, persistent ventricular tachycardia or fibrillation, development of heart blocks, and left ventricular impairment are all associated with poorer prognosis.<sup>[16]</sup> Without treatment, about a quarter of those affected by MI die within minutes, and about forty percent within the first month.<sup>[16]</sup> Morbidity and mortality from myocardial infarction has however improved over the years due to earlier and better treatment:<sup>[26]</sup> in those who have an STEMI in the United States, between 5 and 6 percent die before leaving the hospital and 7 to 18 percent die within a year.<sup>[19]</sup>

It is unusual for babies to experience a myocardial infarction, but when they do, about half die.<sup>[124]</sup> In the short-term, neonatal survivors seem to have a normal quality of life.<sup>[124]</sup>

## Complications

Complications may occur immediately following the myocardial infarction or may take time to develop. Disturbances of heart rhythms, including atrial fibrillation, ventricular tachycardia and fibrillation and heart block can arise as a result of ischemia, cardiac scarring, and infarct location.<sup>[16][64]</sup> Stroke is also a risk, either as a result of clots transmitted from the heart during PCI, as a result of bleeding following anticoagulation, or as a result of disturbances in the heart's ability to pump effectively as a result of the infarction.<sup>[64]</sup> Regurgitation of blood through the mitral valve is possible, particularly if the infarction causes dysfunction of the papillary muscle.<sup>[64]</sup> Cardiogenic shock as a result of the heart being unable to adequately pump blood may develop, dependent on infarct size, and is most likely to occur within the days following an acute myocardial infarction. Cardiogenic shock is the largest cause of in-hospital mortality.<sup>[26][64]</sup> Rupture of the ventricular dividing wall or left ventricular wall may occur within the initial weeks.<sup>[64]</sup> Dressler's syndrome, a reaction following larger infarcts and a cause of pericarditis is also possible.<sup>[64]</sup>

Heart failure may develop as a long-term consequence, with an impaired ability of heart muscle to pump, scarring, and increase in size of the existing muscle. Aneurysm of the left ventricle myocardium develops in about 10% of MI and is itself a risk factor for heart failure, ventricular arrhythmia and the development of clots.<sup>[16]</sup>

Risk factors for complications and death include age, hemodynamic parameters (such as heart failure, cardiac arrest on admission, systolic blood pressure, or Killip class of two or greater), ST-segment deviation, diabetes, serum creatinine, peripheral vascular disease, and elevation of cardiac markers.<sup>[125][126][127]</sup>

## Epidemiology

---

Myocardial infarction is a common presentation of coronary artery disease. The World Health Organization estimated in 2004, that 12.2% of worldwide deaths were from ischemic heart disease;<sup>[128]</sup> with it being the leading cause of death in high- or middle-income countries and second only to lower respiratory infections in lower-income countries.<sup>[128]</sup> Worldwide, more than 3 million people have STEMIs and 4 million have NSTEMIs a year.<sup>[18]</sup> STEMIs occur about twice as often in men as women.<sup>[19]</sup>

Rates of death from ischemic heart disease (IHD) have slowed or declined in most high-income countries, although cardiovascular disease still accounted for one in three of all deaths in the US in 2008.<sup>[129]</sup> For example, rates of death from cardiovascular disease have decreased almost a third between 2001 and 2011 in the United States.<sup>[130]</sup>

In contrast, IHD is becoming a more common cause of death in the developing world. For example, in India, IHD had become the leading cause of death by 2004, accounting for 1.46 million deaths (14% of total deaths) and deaths due to IHD were expected to double during 1985–2015.<sup>[131]</sup> Globally, disability adjusted life years (DALYs) lost to ischemic heart disease are predicted to account for 5.5% of total DALYs in 2030, making it the second-most-important cause of disability (after unipolar depressive disorder), as well as the leading cause of death by this date.<sup>[128]</sup>

## Society and culture

---

Depictions of heart attacks in popular media often include collapsing or loss of consciousness which are not common symptoms; these depictions contribute to widespread misunderstanding about the symptoms of myocardial infarctions, which in turn contributes to people not getting care when they should.<sup>[132]</sup>

## Legal implications

At common law, in general, a myocardial infarction is a disease, but may sometimes be an injury. This can create coverage issues in the administration of no-fault insurance schemes such as workers' compensation. In general, a heart attack is not covered;<sup>[133]</sup> however, it may be a work-related injury if it results, for example, from unusual emotional stress or unusual exertion.<sup>[134]</sup> In addition, in some jurisdictions, heart attacks suffered by persons in particular occupations such as police officers may be classified as line-of-duty injuries by statute or policy. In some countries or states, a person having suffered from an MI may be prevented from participating in activity that puts other people's lives at risk, for example driving a car or flying an airplane.<sup>[135]</sup>

## References

---

1. "What Are the Signs and Symptoms of Coronary Heart Disease?" (<http://www.nhlbi.nih.gov/health/health-topics/topics/cad/signs>). *www.nhlbi.nih.gov*. September 29, 2014. Archived (<https://web.archive.org/web/20150224034615/http://www.nhlbi.nih.gov/health/health-topics/topics/cad/signs>) from the original on 24 February 2015. Retrieved 23 February 2015.
2. "Heart Attack Symptoms in Women" (<https://www.heart.org/en/health-topics/heart-attack/warning-signs-of-a-heart-attack/heart-attack-symptoms-in-women>). *American Heart Association*.
3. "What Is a Heart Attack?" (<http://www.nhlbi.nih.gov/health/health-topics/topics/heartattack/>). *www.nhlbi.nih.gov*. December 17, 2013. Archived (<https://web.archive.org/web/20150219152830/http://www.nhlbi.nih.gov/health/health-topics/topics/heartattack/>) from the original on 19 February 2015. Retrieved 24 February 2015.

4. "Heart Attack or Sudden Cardiac Arrest: How Are They Different?" ([http://www.heart.org/HEARTORG/Conditions/More/MyHeartandStrokeNews/Heart-Attack-or-Sudden-Cardiac-Arrest-How-Are-They-Different\\_UCM\\_440804\\_Article.jsp](http://www.heart.org/HEARTORG/Conditions/More/MyHeartandStrokeNews/Heart-Attack-or-Sudden-Cardiac-Arrest-How-Are-They-Different_UCM_440804_Article.jsp)). *www.heart.org*. Jul 30, 2014. Archived ([https://web.archive.org/web/20150224045054/http://www.heart.org/HEARTORG/Conditions/More/MyHeartandStrokeNews/Heart-Attack-or-Sudden-Cardiac-Arrest-How-Are-They-Different\\_UCM\\_440804\\_Article.jsp](https://web.archive.org/web/20150224045054/http://www.heart.org/HEARTORG/Conditions/More/MyHeartandStrokeNews/Heart-Attack-or-Sudden-Cardiac-Arrest-How-Are-They-Different_UCM_440804_Article.jsp)) from the original on 24 February 2015. Retrieved 24 February 2015.
5. Mehta PK, Wei J, Wenger NK (February 2015). "Ischemic heart disease in women: a focus on risk factors" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336825>). *Trends in Cardiovascular Medicine*. **25** (2): 140–51. doi:10.1016/j.tcm.2014.10.005 (<https://doi.org/10.1016%2Fj.tcm.2014.10.005>). PMC 4336825 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336825>). PMID 25453985 (<https://pubmed.ncbi.nlm.nih.gov/25453985>).
6. Mendis S, Puska P, Norrving B (2011). *Global atlas on cardiovascular disease prevention and control* ([http://whqlibdoc.who.int/publications/2011/9789241564373\\_eng.pdf?ua=1](http://whqlibdoc.who.int/publications/2011/9789241564373_eng.pdf?ua=1)) (PDF) (1st ed.). Geneva: World Health Organization in collaboration with the World Heart Federation and the World Stroke Organization. pp. 3–18. ISBN 978-92-4-156437-3. Archived ([https://web.archive.org/web/20140817123106/http://whqlibdoc.who.int/publications/2011/9789241564373\\_eng.pdf?ua=1](https://web.archive.org/web/20140817123106/http://whqlibdoc.who.int/publications/2011/9789241564373_eng.pdf?ua=1)) (PDF) from the original on 2014-08-17.
7. "How Is a Heart Attack Diagnosed?" (<http://www.nhlbi.nih.gov/health/health-topics/topics/heartattack/diagnosis>). *www.nhlbi.nih.gov*. December 17, 2013. Archived (<https://web.archive.org/web/20150224044949/http://www.nhlbi.nih.gov/health/health-topics/topics/heartattack/diagnosis>) from the original on 24 February 2015. Retrieved 24 February 2015.
8. Steg PG, James SK, Atar D, Badano LP, Blömmestrom-Lundqvist C, Borger MA, et al. (October 2012). "ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation". *European Heart Journal*. **33** (20): 2569–619. doi:10.1093/eurheartj/ehs215 (<https://doi.org/10.1093%2Feurheartj%2Fehs215>). PMID 22922416 (<https://pubmed.ncbi.nlm.nih.gov/22922416>).
9. O'Connor RE, Brady W, Brooks SC, Diercks D, Egan J, Ghaemmaghami C, et al. (November 2010). "Part 10: acute coronary syndromes: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care". *Circulation*. **122** (18 Suppl 3): S787–817. doi:10.1161/CIRCULATIONAHA.110.971028 (<https://doi.org/10.1161%2FCIRCULATIONAHA.110.971028>). PMID 20956226 (<https://pubmed.ncbi.nlm.nih.gov/20956226>).
10. Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, et al. (GBD 2015 Disease Injury Incidence Prevalence Collaborators) (October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055577>). *Lancet*. **388** (10053): 1545–1602. doi:10.1016/S0140-6736(16)31678-6 (<https://doi.org/10.1016%2FS0140-6736%2816%2931678-6>). PMC 5055577 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055577>). PMID 27733282 (<https://pubmed.ncbi.nlm.nih.gov/27733282>).
11. Coventry LL, Finn J, Bremner AP (2011). "Sex differences in symptom presentation in acute myocardial infarction: a systematic review and meta-analysis". *Heart & Lung*. **40** (6): 477–91. doi:10.1016/j.hrtlng.2011.05.001 (<https://doi.org/10.1016%2Fj.hrtlng.2011.05.001>). PMID 22000678 (<https://pubmed.ncbi.nlm.nih.gov/22000678>).
12. Valensi P, Lorgis L, Cottin Y (March 2011). "Prevalence, incidence, predictive factors and prognosis of silent myocardial infarction: a review of the literature". *Archives of Cardiovascular Diseases*. **104** (3): 178–88. doi:10.1016/j.acvd.2010.11.013 (<https://doi.org/10.1016%2Fj.acvd.2010.11.013>). PMID 21497307 (<https://pubmed.ncbi.nlm.nih.gov/21497307>).

13. "What Causes a Heart Attack?" (<http://www.nhlbi.nih.gov/health/health-topics/topics/heartattack/causes>). *www.nhlbi.nih.gov*. December 17, 2013. Archived (<https://web.archive.org/web/20150218075735/http://www.nhlbi.nih.gov/health/health-topics/topics/heartattack/causes>) from the original on 18 February 2015. Retrieved 24 February 2015.
14. Devlin RJ, Henry JA (2008). "Clinical review: Major consequences of illicit drug consumption" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374627>). *Critical Care*. **12** (1): 202. doi:10.1186/cc6166 (<https://doi.org/10.1186%2Fcc6166>). PMC 2374627 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374627>). PMID 18279535 (<https://pubmed.ncbi.nlm.nih.gov/18279535>).
15. "Electrocardiogram – NHLBI, NIH" (<https://www.nhlbi.nih.gov/health/health-topics/topics/ekg>). *www.nhlbi.nih.gov*. 9 December 2016. Archived (<https://web.archive.org/web/20170411140634/https://www.nhlbi.nih.gov/health/health-topics/topics/ekg>) from the original on 11 April 2017. Retrieved 10 April 2017.
16. Britton, the editors Nicki R. Colledge, Brian R. Walker, Stuart H. Ralston; illustrated by Robert (2010). *Davidson's principles and practice of medicine* (21st ed.). Edinburgh: Churchill Livingstone/Elsevier. pp. 588–599. ISBN 978-0-7020-3085-7.
17. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al. (December 2011). "ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)". *European Heart Journal*. **32** (23): 2999–3054. doi:10.1093/eurheartj/ehr236 (<https://doi.org/10.1093%2Feurheartj%2Fehr236>). PMID 21873419 (<https://pubmed.ncbi.nlm.nih.gov/21873419>).
18. White HD, Chew DP (August 2008). "Acute myocardial infarction" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1931354>). *Lancet*. **372** (9638): 570–84. doi:10.1016/S0140-6736(08)61237-4 (<https://doi.org/10.1016%2FS0140-6736%2808%2961237-4>). PMC 1931354 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1931354>). PMID 18707987 (<https://pubmed.ncbi.nlm.nih.gov/18707987>).
19. O'Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA, et al. (January 2013). "2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines". *Circulation*. **127** (4): e362–425. doi:10.1161/CIR.0b013e3182742cf6 (<https://doi.org/10.1161%2FCIR.0b013e3182742cf6>). PMID 23247304 (<https://pubmed.ncbi.nlm.nih.gov/23247304>).
20. Moran AE, Forouzanfar MH, Roth GA, Mensah GA, Ezzati M, Flaxman A, et al. (April 2014). "The global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 study" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4181601>). *Circulation*. **129** (14): 1493–501. doi:10.1161/circulationaha.113.004046 (<https://doi.org/10.1161%2Fcirculationaha.113.004046>). PMC 4181601 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4181601>). PMID 24573351 (<https://pubmed.ncbi.nlm.nih.gov/24573351>).
21. Torio, Celeste (August 2013). "National Inpatient Hospital Costs: The Most Expensive Conditions by Payer, 2011" (<http://hcup-us.ahrq.gov/reports/statbriefs/sb160.jsp>). *HCUP*. Archived (<https://web.archive.org/web/20170314171958/http://www.hcup-us.ahrq.gov/reports/statbriefs/sb160.jsp>) from the original on 14 March 2017. Retrieved 1 May 2017.
22. Acute Coronary Syndrome (<http://www.americanheart.org/presenter.jhtml?identifier=3010002>). American Heart Association. Retrieved November 25, 2006. Archived (<https://web.archive.org/web/20060925134349/http://www.americanheart.org/presenter.jhtml?identifier=3010002>) September 25, 2006, at the [Wayback Machine](#)
23. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. (October 2012). "Third universal definition of myocardial infarction". *Circulation*. **126** (16): 2020–35. doi:10.1161/CIR.0b013e31826e1058 (<https://doi.org/10.1161%2FCIR.0b013e31826e1058>). PMID 22923432 (<https://pubmed.ncbi.nlm.nih.gov/22923432>).

24. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, et al. (December 2008). "Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology". *European Heart Journal*. **29** (23): 2909–45. doi:10.1093/eurheartj/ehn416 (<https://doi.org/10.1093%2Feurheartj%2Fehn416>). PMID 19004841 (<https://pubmed.ncbi.nlm.nih.gov/19004841>).
25. Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J (2015). *Harrison's principles of internal medicine*. McGraw Hill Education. pp. 1593–1610. ISBN 978-0-07-180215-4. OCLC 923181481 (<https://www.worldcat.org/oclc/923181481>).
26. Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J (2015). *Harrison's Principles of Internal Medicine*. McGraw Hill Education. pp. 98–99. ISBN 978-0-07-180215-4. OCLC 923181481 (<https://www.worldcat.org/oclc/923181481>).
27. Gupta R, Munoz R (August 2016). "Evaluation and Management of Chest Pain in the Elderly". *Emergency Medicine Clinics of North America*. **34** (3): 523–42. doi:10.1016/j.emc.2016.04.006 (<https://doi.org/10.1016%2Fj.emc.2016.04.006>). PMID 27475013 (<https://pubmed.ncbi.nlm.nih.gov/27475013>).
28. Marcus GM, Cohen J, Varosy PD, Vessey J, Rose E, Massie BM, et al. (January 2007). "The utility of gestures in patients with chest discomfort". *The American Journal of Medicine*. **120** (1): 83–9. doi:10.1016/j.amjmed.2006.05.045 (<https://doi.org/10.1016%2Fj.amjmed.2006.05.045>). PMID 17208083 (<https://pubmed.ncbi.nlm.nih.gov/17208083>).
29. "Heart Attack Symptoms in Women" (<https://www.heart.org/en/health-topics/heart-attack/warning-signs-of-a-heart-attack/heart-attack-symptoms-in-women>). *www.heart.org*. Retrieved 2018-11-07.
30. "Signs of a heart attack in women" (<https://www.womenshealth.gov/heart-disease-and-stroke/heart-disease/heart-attack-and-women/heart-attack-symptoms>). *womenshealth.gov*. Retrieved 2018-11-07.
31. Canto JG, Goldberg RJ, Hand MM, Bonow RO, Sopko G, Pepine CJ, Long T (December 2007). "Symptom presentation of women with acute coronary syndromes: myth vs reality". *Archives of Internal Medicine*. **167** (22): 2405–13. doi:10.1001/archinte.167.22.2405 (<https://doi.org/10.1001%2Farchinte.167.22.2405>). PMID 18071161 (<https://pubmed.ncbi.nlm.nih.gov/18071161>).
32. Ashton R, Raman D. "Dyspnea" (<http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/pulmonary/dyspnea/>). *www.clevelandclinicmeded.com*. Cleveland Clinic. Archived (<https://web.archive.org/web/20170711084207/http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/pulmonary/dyspnea/>) from the original on 11 July 2017. Retrieved 24 May 2017.
33. Lilly LS (2012). *Pathophysiology of Heart Disease: A Collaborative Project of Medical Students and Faculty* (<https://books.google.com.au/books?id=0lxSGJYeXikC&pg=PA172&lpg=PA172>). Lippincott Williams & Wilkins. p. 172. ISBN 9781469816685. Archived (<https://web.archive.org/web/20170728135942/https://books.google.com.au/books?id=0lxSGJYeXikC&pg=PA172&lpg=PA172>) from the original on 2017-07-28.
34. Davis TM, Fortun P, Mulder J, Davis WA, Bruce DG (March 2004). "Silent myocardial infarction and its prognosis in a community-based cohort of Type 2 diabetic patients: the Fremantle Diabetes Study". *Diabetologia*. **47** (3): 395–399. doi:10.1007/s00125-004-1344-4 (<https://doi.org/10.1007%2Fs00125-004-1344-4>). PMID 14963648 (<https://pubmed.ncbi.nlm.nih.gov/14963648>).
35. Rubin E, Gorstein F, Rubin R, Schwarting R, Strayer D (2001). *Rubin's Pathology — Clinicopathological Foundations of Medicine*. Maryland: Lippincott Williams & Wilkins. p. 549. ISBN 978-0-7817-4733-2.

36. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. (July 2012). "European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)". *European Heart Journal*. **33** (13): 1635–701. doi:10.1093/eurheartj/ehs092 (<https://doi.org/10.1093%2Feurheartj%2Fehs092>). PMID 22555213 (<https://pubmed.ncbi.nlm.nih.gov/22555213>).
37. Smith SC, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. (May 2006). "AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute". *Journal of the American College of Cardiology*. **47** (10): 2130–9. doi:10.1016/j.jacc.2006.04.026 (<https://doi.org/10.1016%2Fj.jacc.2006.04.026>). PMID 16697342 (<https://pubmed.ncbi.nlm.nih.gov/16697342>).
38. Kivimäki M, Nyberg ST, Batty GD, Fransson EI, Heikkilä K, Alfredsson L, et al. (October 2012). "Job strain as a risk factor for coronary heart disease: a collaborative meta-analysis of individual participant data" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3486012>). *Lancet*. **380** (9852): 1491–7. doi:10.1016/S0140-6736(12)60994-5 (<https://doi.org/10.1016%2FS0140-6736%2812%2960994-5>). PMC 3486012 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3486012>). PMID 22981903 (<https://pubmed.ncbi.nlm.nih.gov/22981903>).
39. Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT (July 2012). "Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3645500>). *Lancet*. **380** (9838): 219–29. doi:10.1016/S0140-6736(12)61031-9 (<https://doi.org/10.1016%2FS0140-6736%2812%2961031-9>). PMC 3645500 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3645500>). PMID 22818936 (<https://pubmed.ncbi.nlm.nih.gov/22818936>).
40. Steptoe A, Kivimäki M (April 2012). "Stress and cardiovascular disease". *Nature Reviews. Cardiology*. **9** (6): 360–70. doi:10.1038/nrcardio.2012.45 (<https://doi.org/10.1038%2Fncardio.2012.45>). PMID 22473079 (<https://pubmed.ncbi.nlm.nih.gov/22473079>).
41. Hooper L, Martin N, Abdelhamid A, Davey Smith G (June 2015). "Reduction in saturated fat intake for cardiovascular disease". *The Cochrane Database of Systematic Reviews*. **6** (6): CD011737. doi:10.1002/14651858.CD011737 (<https://doi.org/10.1002%2F14651858.CD011737>). PMID 26068959 (<https://pubmed.ncbi.nlm.nih.gov/26068959>).
42. Chowdhury R, Warnakula S, Kunutsor S, Crowe F, Ward HA, Johnson L, et al. (March 2014). "Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis". *Annals of Internal Medicine*. **160** (6): 398–406. doi:10.7326/M13-1788 (<https://doi.org/10.7326%2FM13-1788>). PMID 24723079 (<https://pubmed.ncbi.nlm.nih.gov/24723079>).
43. de Souza RJ, Mente A, Maroleanu A, Cozma AI, Ha V, Kishibe T, et al. (August 2015). "Intake of saturated and trans unsaturated fatty acids and risk of all cause mortality, cardiovascular disease, and type 2 diabetes: systematic review and meta-analysis of observational studies" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532752>). *BMJ*. **351**: h3978. doi:10.1136/bmj.h3978 (<https://doi.org/10.1136%2Fbmj.h3978>). PMC 4532752 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532752>). PMID 26268692 (<https://pubmed.ncbi.nlm.nih.gov/26268692>).
44. "Scientific Report of the 2015 Dietary Guidelines Advisory COmmittee" (<https://health.gov/dietaryguidelines/2015-scientific-report/PDFs/Scientific-Report-of-the-2015-Dietary-Guidelines-Advisory-Committee.pdf>) (PDF). *health.gov*. Feb 2015. p. 17. Archived (<https://web.archive.org/web/20160503071439/http://health.gov/dietaryguidelines/2015-scientific-report/PDFs/Scientific-Report-of-the-2015-Dietary-Guidelines-Advisory-Committee.pdf>) (PDF) from the original on 2016-05-03.



45. Krenz M, Korthuis RJ (January 2012). "Moderate ethanol ingestion and cardiovascular protection: from epidemiologic associations to cellular mechanisms" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3246046>). *Journal of Molecular and Cellular Cardiology*. **52** (1): 93–104. doi:10.1016/j.yjmcc.2011.10.011 (<https://doi.org/10.1016%2Fj.yjmcc.2011.10.011>). PMC 3246046 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3246046>). PMID 22041278 (<https://pubmed.ncbi.nlm.nih.gov/22041278>).
46. O'Donnell CJ, Nabel EG (December 2011). "Genomics of cardiovascular disease". *The New England Journal of Medicine*. **365** (22): 2098–109. doi:10.1056/NEJMra1105239 (<https://doi.org/10.1056%2FNEJMra1105239>). PMID 22129254 (<https://pubmed.ncbi.nlm.nih.gov/22129254>).
47. Culić V (April 2007). "Acute risk factors for myocardial infarction". *International Journal of Cardiology*. **117** (2): 260–9. doi:10.1016/j.ijcard.2006.05.011 (<https://doi.org/10.1016%2Fj.ijcard.2006.05.011>). PMID 16860887 (<https://pubmed.ncbi.nlm.nih.gov/16860887>).
48. Shaw E, Tofler GH (July 2009). "Circadian rhythm and cardiovascular disease". *Current Atherosclerosis Reports*. **11** (4): 289–95. doi:10.1007/s11883-009-0044-4 (<https://doi.org/10.1007%2Fs11883-009-0044-4>). PMID 19500492 (<https://pubmed.ncbi.nlm.nih.gov/19500492>).
49. Vyas MV, Garg AX, Iansavichus AV, Costella J, Donner A, Laugsand LE, et al. (July 2012). "Shift work and vascular events: systematic review and meta-analysis" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3406223>). *BMJ*. **345**: e4800. doi:10.1136/bmj.e4800 (<https://doi.org/10.1136%2Fbmj.e4800>). PMC 3406223 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3406223>). PMID 22835925 (<https://pubmed.ncbi.nlm.nih.gov/22835925>).
50. Janszky I, Ljung R (October 2008). "Shifts to and from daylight saving time and incidence of myocardial infarction". *The New England Journal of Medicine*. **359** (18): 1966–8. doi:10.1056/NEJMc0807104 (<https://doi.org/10.1056%2FNEJMc0807104>). PMID 18971502 (<https://pubmed.ncbi.nlm.nih.gov/18971502>).
51. Roach RE, Helmerhorst FM, Lijfering WM, Stijnen T, Algra A, Dekkers OM (August 2015). "Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke" (<http://dSPACE.library.uu.nl/handle/1874/340787>). *The Cochrane Database of Systematic Reviews* (8): CD011054. doi:10.1002/14651858.CD011054.pub2 (<https://doi.org/10.1002%2F14651858.CD011054.pub2>). PMC 6494192 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494192>). PMID 26310586 (<https://pubmed.ncbi.nlm.nih.gov/26310586>).
52. Bally M, Dendukuri N, Rich B, Nadeau L, Helin-Salmivaara A, Garbe E, Brophy JM (May 2017). "Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423546>). *BMJ*. **357**: j1909. doi:10.1136/bmj.j1909 (<https://doi.org/10.1136%2Fbmj.j1909>). PMC 5423546 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423546>). PMID 28487435 (<https://pubmed.ncbi.nlm.nih.gov/28487435>).
53. Mu F, Rich-Edwards J, Rimm EB, Spiegelman D, Missmer SA (May 2016). "Endometriosis and Risk of Coronary Heart Disease" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940126>). *Circulation: Cardiovascular Quality and Outcomes*. **9** (3): 257–64. doi:10.1161/CIRCOUTCOMES.115.002224 (<https://doi.org/10.1161%2FCIRCOUTCOMES.115.002224>). PMC 4940126 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940126>). PMID 27025928 (<https://pubmed.ncbi.nlm.nih.gov/27025928>).
54. Mustafic H, Jabre P, Caussin C, Murad MH, Escolano S, Tafflet M, et al. (February 2012). "Main air pollutants and myocardial infarction: a systematic review and meta-analysis". *JAMA*. **307** (7): 713–21. doi:10.1001/jama.2012.126 (<https://doi.org/10.1001%2Fjama.2012.126>). PMID 22337682 (<https://pubmed.ncbi.nlm.nih.gov/22337682>).

55. Ho AF, Wah W, Earnest A, Ng YY, Xie Z, Shahidah N, et al. (November 2018). "Health impacts of the Southeast Asian haze problem - A time-stratified case crossover study of the relationship between ambient air pollution and sudden cardiac deaths in Singapore". *International Journal of Cardiology*. **271**: 352–358. doi:10.1016/j.ijcard.2018.04.070 (<https://doi.org/10.1016%2Fj.ijcard.2018.04.070>). PMID 30223374 (<https://pubmed.ncbi.nlm.nih.gov/30223374>).
56. Sun Z, Chen C, Xu D, Li T (October 2018). "Effects of ambient temperature on myocardial infarction: A systematic review and meta-analysis". *Environmental Pollution*. **241**: 1106–1114. doi:10.1016/j.envpol.2018.06.045 (<https://doi.org/10.1016%2Fj.envpol.2018.06.045>). PMID 30029319 (<https://pubmed.ncbi.nlm.nih.gov/30029319>).
57. Chatzidimitriou D, Kirmizis D, Gavrilaki E, Chatzidimitriou M, Malisiovas N (October 2012). "Atherosclerosis and infection: is the jury still not in?". *Future Microbiology*. **7** (10): 1217–30. doi:10.2217/fmb.12.87 (<https://doi.org/10.2217%2Ffmb.12.87>). PMID 23030426 (<https://pubmed.ncbi.nlm.nih.gov/23030426>).
58. Charakida M, Tousoulis D (2013). "Infections and atheromatous plaque: current therapeutic implications". *Current Pharmaceutical Design*. **19** (9): 1638–50. doi:10.2174/138161213805219658 (<https://doi.org/10.2174%2F138161213805219658>). PMID 23016720 (<https://pubmed.ncbi.nlm.nih.gov/23016720>).
59. Sánchez-Manubens J, Bou R, Anton J (February 2014). "Diagnosis and classification of Kawasaki disease". *Journal of Autoimmunity*. 48-49: 113–7. doi:10.1016/j.jaut.2014.01.010 (<https://doi.org/10.1016%2Fj.jaut.2014.01.010>). PMID 24485156 (<https://pubmed.ncbi.nlm.nih.gov/24485156>).
60. Hulten EA, Carbonaro S, Petrillo SP, Mitchell JD, Villines TC (March 2011). "Prognostic value of cardiac computed tomography angiography: a systematic review and meta-analysis". *Journal of the American College of Cardiology*. **57** (10): 1237–47. doi:10.1016/j.jacc.2010.10.011 (<https://doi.org/10.1016%2Fj.jacc.2010.10.011>). PMID 21145688 (<https://pubmed.ncbi.nlm.nih.gov/21145688>).
61. Clarke R, Halsey J, Bennett D, Lewington S (February 2011). "Homocysteine and vascular disease: review of published results of the homocysteine-lowering trials". *Journal of Inherited Metabolic Disease*. **34** (1): 83–91. doi:10.1007/s10545-010-9235-y (<https://doi.org/10.1007%2Fs10545-010-9235-y>). PMID 21069462 (<https://pubmed.ncbi.nlm.nih.gov/21069462>).
62. Lonn E (September 2007). "Homocysteine in the prevention of ischemic heart disease, stroke and venous thromboembolism: therapeutic target or just another distraction?". *Current Opinion in Hematology*. **14** (5): 481–7. doi:10.1097/MOH.0b013e3282c48bd8 (<https://doi.org/10.1097%2FMOH.0b013e3282c48bd8>). PMID 17934354 (<https://pubmed.ncbi.nlm.nih.gov/17934354>).
63. Agewall S, Beltrame JF, Reynolds HR, Niessner A, Rosano G, Caforio AL, et al. (January 2017). "ESC working group position paper on myocardial infarction with non-obstructive coronary arteries". *European Heart Journal*. **38** (3): 143–153. doi:10.1093/eurheartj/ehw149 (<https://doi.org/10.1093%2Feurheartj%2Fehw149>). PMID 28158518 (<https://pubmed.ncbi.nlm.nih.gov/28158518>).
64. Reed GW, Rossi JE, Cannon CP (January 2017). "Acute myocardial infarction". *Lancet*. **389** (10065): 197–210. doi:10.1016/S0140-6736(16)30677-8 (<https://doi.org/10.1016%2FS0140-6736%2816%2930677-8>). PMID 27502078 (<https://pubmed.ncbi.nlm.nih.gov/27502078>).
65. Britton, the editors Nicki R. Colledge, Brian R. Walker, Stuart H. Ralston; illustrated by Robert (2010). *Davidson's principles and practice of medicine* (21st ed.). Edinburgh: Churchill Livingstone/Elsevier. pp. 577–9. ISBN 978-0-7020-3085-7.
66. Woollard KJ, Geissmann F (February 2010). "Monocytes in atherosclerosis: subsets and functions" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2813241>). *Nature Reviews. Cardiology*. **7** (2): 77–86. doi:10.1038/nrcardio.2009.228 (<https://doi.org/10.1038%2Fncardio.2009.228>). PMC 2813241 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2813241>). PMID 20065951 (<https://pubmed.ncbi.nlm.nih.gov/20065951>).

67. Janoudi A, Shamoun FE, Kalavakunta JK, Abela GS (July 2016). "Cholesterol crystal induced arterial inflammation and destabilization of atherosclerotic plaque". *European Heart Journal*. **37** (25): 1959–67. doi:10.1093/eurheartj/ehv653 (<https://doi.org/10.1093%2Feurheartj%2Fehv653>). PMID 26705388 (<https://pubmed.ncbi.nlm.nih.gov/26705388>).
68. Buja LM (July 2005). "Myocardial ischemia and reperfusion injury". *Cardiovascular Pathology*. **14** (4): 170–5. doi:10.1016/j.carpath.2005.03.006 (<https://doi.org/10.1016%2Fj.carpath.2005.03.006>). PMID 16009313 (<https://pubmed.ncbi.nlm.nih.gov/16009313>).
69. Bolooki HM, Askari A (August 2010). "Acute Myocardial Infarction" (<http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/cardiology/acute-myocardial-infarction/>). *www.clevelandclinicmeded.com*. Archived (<https://web.archive.org/web/20170428050921/http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/cardiology/acute-myocardial-infarction/>) from the original on 28 April 2017. Retrieved 24 May 2017.
70. Connolly, Philip I. Aaronson, Jeremy P.T. Ward, Michelle J. (2013). *The cardiovascular system at a glance* (4th ed.). Chichester, West Sussex: Wiley-Blackwell. pp. 88–89. ISBN 978-0-470-65594-8.
71. Kutty RS, Jones N, Moorjani N (November 2013). "Mechanical complications of acute myocardial infarction". *Cardiology Clinics* (Review). **31** (4): 519–31, vii–viii. doi:10.1016/j.ccl.2013.07.004 (<https://doi.org/10.1016%2Fj.ccl.2013.07.004>). PMID 24188218 (<https://pubmed.ncbi.nlm.nih.gov/24188218>).
72. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD (January 2019). "Fourth universal definition of myocardial infarction (2018)". *European Heart Journal*. **40** (3): 237–269. doi:10.1093/eurheartj/ehy462 (<https://doi.org/10.1093%2Feurheartj%2Fehy462>). PMID 30165617 (<https://pubmed.ncbi.nlm.nih.gov/30165617>).
73. Pickering JW, Than MP, Cullen L, Aldous S, Ter Avest E, Body R, et al. (May 2017). "Rapid Rule-out of Acute Myocardial Infarction With a Single High-Sensitivity Cardiac Troponin T Measurement Below the Limit of Detection: A Collaborative Meta-analysis" ([https://www.research.manchester.ac.uk/portal/en/publications/rapid-ruleout-of-acute-myocardial-infarction-with-a-single-highsensitivity-cardiac-troponin-t-measurement-below-the-limit-of-detection\(0e2cb8e0-229a-446b-9389-7fa319a649d4\).html](https://www.research.manchester.ac.uk/portal/en/publications/rapid-ruleout-of-acute-myocardial-infarction-with-a-single-highsensitivity-cardiac-troponin-t-measurement-below-the-limit-of-detection(0e2cb8e0-229a-446b-9389-7fa319a649d4).html)). *Annals of Internal Medicine*. **166** (10): 715–724. doi:10.7326/M16-2562 (<https://doi.org/10.7326%2FM16-2562>). PMID 28418520 (<https://pubmed.ncbi.nlm.nih.gov/28418520>).
74. Chapman AR, Lee KK, McAllister DA, Cullen L, Greenslade JH, Parsonage W, et al. (November 2017). "Association of High-Sensitivity Cardiac Troponin I Concentration With Cardiac Outcomes in Patients With Suspected Acute Coronary Syndrome" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710293>). *JAMA*. **318** (19): 1913–1924. doi:10.1001/jama.2017.17488 (<https://doi.org/10.1001%2Fjama.2017.17488>). PMC 5710293 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710293>). PMID 29127948 (<https://pubmed.ncbi.nlm.nih.gov/29127948>).
75. Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Ganiats TG, Holmes DR, et al. (December 2014). "2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines". *Circulation*. **130** (25): e344–426. doi:10.1161/CIR.0000000000000134 (<https://doi.org/10.1161%2FCIR.0000000000000134>). PMID 25249585 (<https://pubmed.ncbi.nlm.nih.gov/25249585>).
76. Lipinski MJ, Escárcega RO, D'Ascenzo F, Magalhães MA, Baker NC, Torguson R, et al. (May 2014). "A systematic review and collaborative meta-analysis to determine the incremental value of copeptin for rapid rule-out of acute myocardial infarction". *The American Journal of Cardiology*. **113** (9): 1581–91. doi:10.1016/j.amjcard.2014.01.436 (<https://doi.org/10.1016%2Fj.amjcard.2014.01.436>). PMID 24731654 (<https://pubmed.ncbi.nlm.nih.gov/24731654>).
77. Britton, the editors Nicki R. Colledge, Brian R. Walker, Stuart H. Ralston; illustrated by Robert (2010). *Davidson's principles and practice of medicine* (21st ed.). Edinburgh: Churchill Livingstone/Elsevier. pp. 529–30. ISBN 978-0-7020-3085-7.

78. Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J (2015). *Harrison's principles of internal medicine*. McGraw Hill Education. p. 1457. ISBN 978-0-07-180215-4. OCLC 923181481 (<https://www.worldcat.org/oclc/923181481>).
79. "American College of Cardiology" (<http://www.choosingwisely.org/societies/american-college-of-cardiology/>). *www.choosingwisely.org*. Choosing Wisely. 28 February 2017. Archived (<https://web.archive.org/web/20170728125746/http://www.choosingwisely.org/societies/american-college-of-cardiology/>) from the original on 28 July 2017. Retrieved 24 May 2017.
80. Schinkel AF, Valkema R, Geleijnse ML, Sijbrands EJ, Poldermans D (May 2010). "Single-photon emission computed tomography for assessment of myocardial viability". *EuroIntervention*. 6 Suppl G (Supplement G): G115–22. PMID 20542817 (<https://pubmed.ncbi.nlm.nih.gov/20542817>).
81. National Institute for Health and Clinical Excellence. *Clinical guideline cg94: Unstable angina and NSTEMI* (<https://www.nice.org.uk/guidance/CGcg94>). London, 2010.
82. "UOTW #36 - Ultrasound of the Week" (<https://www.ultrasoundoftheweek.com/uotw-36/>). *Ultrasound of the Week*. 5 February 2015. Archived (<https://web.archive.org/web/20170509115806/https://www.ultrasoundoftheweek.com/uotw-36/>) from the original on 9 May 2017. Retrieved 27 May 2017.
83. Britton, the editors Nicki R. Colledge, Brian R. Walker, Stuart H. Ralston; illustrated by Robert (2010). *Davidson's principles and practice of medicine* (21st ed.). Edinburgh: Churchill Livingstone/Elsevier. pp. 535, 539. ISBN 978-0-7020-3085-7.
84. Boie ET (November 2005). "Initial evaluation of chest pain". *Emergency Medicine Clinics of North America*. 23 (4): 937–57. doi:10.1016/j.emc.2005.07.007 (<https://doi.org/10.1016%2Fj.emc.2005.07.007>). PMID 16199332 (<https://pubmed.ncbi.nlm.nih.gov/16199332>).
85. "Assessment of fatigue" (<http://bestpractice.bmj.com/best-practice/monograph/571/diagnosis/differential-diagnosis.html>). *BMJ Best Practice*. 17 August 2016. Retrieved 6 June 2017.
86. Hess EP, Agarwal D, Chandra S, Murad MH, Erwin PJ, Hollander JE, et al. (July 2010). "Diagnostic accuracy of the TIMI risk score in patients with chest pain in the emergency department: a meta-analysis" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2900327>). *CMAJ*. 182 (10): 1039–44. doi:10.1503/cmaj.092119 (<https://doi.org/10.1503%2Fcmaj.092119>). PMC 2900327 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2900327>). PMID 20530163 (<https://pubmed.ncbi.nlm.nih.gov/20530163>).
87. Reeder, Guy (27 December 2016). "Nitrates in the management of acute coronary syndrome" (<https://www.uptodate.com/contents/nitrates-in-the-management-of-acute-coronary-syndrome>). *www.uptodate.com*. Archived (<https://web.archive.org/web/20170728135423/https://www.uptodate.com/contents/nitrates-in-the-management-of-acute-coronary-syndrome>) from the original on 28 July 2017. Retrieved 24 May 2017.
88. Yadlapati A, Gajjar M, Schimmel DR, Ricciardi MJ, Flaherty JD (December 2016). "Contemporary management of ST-segment elevation myocardial infarction". *Internal and Emergency Medicine*. 11 (8): 1107–1113. doi:10.1007/s11739-016-1550-3 (<https://doi.org/10.1007%2Fs11739-016-1550-3>). PMID 27714584 (<https://pubmed.ncbi.nlm.nih.gov/27714584>).
89. McCarthy CP, Mullins KV, Sidhu SS, Schulman SP, McEvoy JW (June 2016). "The on- and off-target effects of morphine in acute coronary syndrome: A narrative review". *American Heart Journal*. 176: 114–21. doi:10.1016/j.ahj.2016.04.004 (<https://doi.org/10.1016%2Fj.ahj.2016.04.004>). PMID 27264228 (<https://pubmed.ncbi.nlm.nih.gov/27264228>).
90. Bellemain-Appaix A, Kerneis M, O'Connor SA, Silvain J, Cucherat M, Beygui F, et al. (October 2014). "Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4208629>). *BMJ*. 349: g6269. doi:10.1136/bmj.g6269 (<https://doi.org/10.1136%2Fbmj.g6269>). PMC 4208629 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4208629>). PMID 25954988 (<https://pubmed.ncbi.nlm.nih.gov/25954988>).

91. Andrade-Castellanos CA, Colunga-Lozano LE, Delgado-Figueroa N, Magee K (June 2014). "Heparin versus placebo for non-ST elevation acute coronary syndromes" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769062>). *The Cochrane Database of Systematic Reviews*. **6** (6): CD003462. doi:10.1002/14651858.CD003462.pub3 (<https://doi.org/10.1002%2F14651858.CD003462.pub3>). PMC 6769062 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769062>). PMID 24972265 (<https://pubmed.ncbi.nlm.nih.gov/24972265>).
92. Bagai A, Dargas GD, Stone GW, Granger CB (June 2014). "Reperfusion strategies in acute coronary syndromes". *Circulation Research*. **114** (12): 1918–28. doi:10.1161/CIRCRESAHA.114.302744 (<https://doi.org/10.1161%2FCIRCRESAHA.114.302744>). PMID 24902975 (<https://pubmed.ncbi.nlm.nih.gov/24902975>).
93. Jobs A, Mehta SR, Montalescot G, Vicaut E, Van't Hof AW, Badings EA, et al. (August 2017). "Optimal timing of an invasive strategy in patients with non-ST-elevation acute coronary syndrome: a meta-analysis of randomised trials". *Lancet*. **390** (10096): 737–746. doi:10.1016/S0140-6736(17)31490-3 (<https://doi.org/10.1016%2FS0140-6736%2817%2931490-3>). PMID 28778541 (<https://pubmed.ncbi.nlm.nih.gov/28778541>).
94. Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, et al. (October 2010). "Guidelines on myocardial revascularization". *European Heart Journal*. **31** (20): 2501–55. doi:10.1093/eurheartj/ehq277 (<https://doi.org/10.1093%2Feurheartj%2Fehq277>). PMID 20802248 (<https://pubmed.ncbi.nlm.nih.gov/20802248>).
95. Dalal F, Dalal HM, Voukalis C, Gandhi MM (July 2017). "Management of patients after primary percutaneous coronary intervention for myocardial infarction" (<https://semanticscholar.org/paper/0ae24ba672e3ba8378deea704b0c5e584abbefb2>) (Submitted manuscript). *BMJ*. **358**: j3237. doi:10.1136/bmj.j3237 (<https://doi.org/10.1136%2Fbmj.j3237>). PMID 28729460 (<https://pubmed.ncbi.nlm.nih.gov/28729460>).
96. Lassen JF, Bøtker HE, Terkelsen CJ (January 2013). "Timely and optimal treatment of patients with STEMI". *Nature Reviews. Cardiology*. **10** (1): 41–8. doi:10.1038/nrcardio.2012.156 (<https://doi.org/10.1038%2Fnrcardio.2012.156>). PMID 23165072 (<https://pubmed.ncbi.nlm.nih.gov/23165072>).
97. Neumar RW, Shuster M, Callaway CW, Gent LM, Atkins DL, Bhanji F, et al. (November 2015). "Part 1: Executive Summary: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care". *Circulation*. **132** (18 Suppl 2): S315–67. doi:10.1161/cir.0000000000000252 (<https://doi.org/10.1161%2Fcir.0000000000000252>). PMID 26472989 (<https://pubmed.ncbi.nlm.nih.gov/26472989>).
98. McCaul M, Lourens A, Kredo T (September 2014). "Pre-hospital versus in-hospital thrombolysis for ST-elevation myocardial infarction" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823254>). *The Cochrane Database of Systematic Reviews*. **9** (9): CD010191. doi:10.1002/14651858.CD010191.pub2 (<https://doi.org/10.1002%2F14651858.CD010191.pub2>). PMC 6823254 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823254>). PMID 25208209 (<https://pubmed.ncbi.nlm.nih.gov/25208209>).
99. Cabello JB, Burls A, Emparanza JI, Bayliss SE, Quinn T (December 2016). "Oxygen therapy for acute myocardial infarction" ([http://www.scielo.br/scielo.php?script=sci\\_arttext&pid=S1516-31802010000600013](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802010000600013)). *The Cochrane Database of Systematic Reviews*. **12**: CD007160. doi:10.1002/14651858.CD007160.pub4 (<https://doi.org/10.1002%2F14651858.CD007160.pub4>). PMC 6463792 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463792>). PMID 27991651 (<https://pubmed.ncbi.nlm.nih.gov/27991651>).
100. Hofmann R, James SK, Jernberg T, Lindahl B, Erlinge D, Witt N, et al. (September 2017). "Oxygen Therapy in Suspected Acute Myocardial Infarction". *The New England Journal of Medicine*. **377** (13): 1240–1249. doi:10.1056/nejmoa1706222 (<https://doi.org/10.1056%2Fnejmoa1706222>). PMID 28844200 (<https://pubmed.ncbi.nlm.nih.gov/28844200>).

101. Abuzaid A, Fabrizio C, Felpel K, Al Ashry HS, Ranjan P, Elbadawi A, et al. (June 2018). "Oxygen Therapy in Patients with Acute Myocardial Infarction: A Systemic Review and Meta-Analysis". *The American Journal of Medicine*. **131** (6): 693–701. doi:10.1016/j.amjmed.2017.12.027 (<https://doi.org/10.1016%2Fj.amjmed.2017.12.027>). PMID 29355510 (<https://pubmed.ncbi.nlm.nih.gov/29355510>).
102. Sepehrvand N, James SK, Stub D, Khoshnood A, Ezekowitz JA, Hofmann R (October 2018). "Effects of supplemental oxygen therapy in patients with suspected acute myocardial infarction: a meta-analysis of randomised clinical trials". *Heart*. **104** (20): 1691–1698. doi:10.1136/heartjnl-2018-313089 (<https://doi.org/10.1136%2Fheartjnl-2018-313089>). PMID 29599378 (<https://pubmed.ncbi.nlm.nih.gov/29599378>).
103. Ardehali R, Perez M, Wang P (2011). *A practical approach to cardiovascular medicine* (<https://books.google.com/books?id=LZsoHMN8IM4C&pg=PA57>). Chichester, West Sussex, UK: Wiley-Blackwell. p. 57. ISBN 978-1-4443-9387-3.
104. Jindal SK, ed. (2011). *Textbook of pulmonary and critical care medicine* (<https://books.google.com/books?id=rAT1bdnDakAC&pg=PA1758>). New Delhi: Jaypee Brothers Medical Publishers. p. 1758. ISBN 978-93-5025-073-0.
105. Dahal K, Hendrani A, Sharma SP, Singireddy S, Mina G, Reddy P, et al. (July 2018). "Aldosterone Antagonist Therapy and Mortality in Patients With ST-Segment Elevation Myocardial Infarction Without Heart Failure: A Systematic Review and Meta-analysis" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145720>). *JAMA Internal Medicine*. **178** (7): 913–920. doi:10.1001/jamainternmed.2018.0850 (<https://doi.org/10.1001%2Fjamainternmed.2018.0850>). PMC 6145720 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145720>). PMID 29799995 (<https://pubmed.ncbi.nlm.nih.gov/29799995>).
106. National Institute for Health and Clinical Excellence. *Clinical guideline 172: Secondary prevention in primary and secondary care for patients following a myocardial infarction* (<https://www.nice.org.uk/guidance/CG172>). London, 2013.
107. National Institute for Health and Clinical Excellence. *Clinical guideline 181: Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease* (<https://www.nice.org.uk/guidance/CG181>). London, 2014.
108. Stradling C, Hamid M, Taheri S, Thomas GN (2014). "A review of dietary influences on cardiovascular health: part 2: dietary patterns". *Cardiovascular & Hematological Disorders Drug Targets*. **14** (1): 50–63. doi:10.2174/1871529x14666140701095426 (<https://doi.org/10.2174%2F1871529x14666140701095426>). PMID 24993125 (<https://pubmed.ncbi.nlm.nih.gov/24993125>).
109. Fortmann SP, Burda BU, Senger CA, Lin JS, Whitlock EP (December 2013). "Vitamin and mineral supplements in the primary prevention of cardiovascular disease and cancer: An updated systematic evidence review for the U.S. Preventive Services Task Force". *Annals of Internal Medicine*. **159** (12): 824–34. doi:10.7326/0003-4819-159-12-201312170-00729 (<https://doi.org/10.7326%2F0003-4819-159-12-201312170-00729>). PMID 24217421 (<https://pubmed.ncbi.nlm.nih.gov/24217421>).
110. McPherson K, et al. (June 2010). "Prevention of cardiovascular disease – NICE public health guidance 25" (<http://guidance.nice.org.uk/ph25>). London: National Institute for Health and Care Excellence. Archived (<https://web.archive.org/web/20140329171156/http://guidance.nice.org.uk/PH25>) from the original on 2014-03-29.
111. Ebrahim S, Taylor F, Ward K, Beswick A, Burke M, Davey Smith G (January 2011). "Multiple risk factor interventions for primary prevention of coronary heart disease" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4160097>). *The Cochrane Database of Systematic Reviews* (1): CD001561. doi:10.1002/14651858.cd001561.pub3 (<https://doi.org/10.1002%2F14651858.cd001561.pub3>). PMC 4160097 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4160097>). PMID 21249647 (<https://pubmed.ncbi.nlm.nih.gov/21249647>).



112. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, et al. (January 2013). "Statins for the primary prevention of cardiovascular disease" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481400>). *The Cochrane Database of Systematic Reviews*. **1** (1): CD004816. doi:10.1002/14651858.CD004816.pub5 (<https://doi.org/10.1002%2F14651858.CD004816.pub5>). PMC 6481400 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481400>). PMID 23440795 (<https://pubmed.ncbi.nlm.nih.gov/23440795>).
113. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. (May 2009). "Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2715005>). *Lancet*. **373** (9678): 1849–60. doi:10.1016/S0140-6736(09)60503-1 (<https://doi.org/10.1016%2FS0140-6736%2809%2960503-1>). PMC 2715005 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2715005>). PMID 19482214 (<https://pubmed.ncbi.nlm.nih.gov/19482214>).
114. Sutcliffe P, Connock M, Gurung T, Freeman K, Johnson S, Kandala NB, et al. (September 2013). "Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4781046>). *Health Technology Assessment*. **17** (43): 1–253. doi:10.3310/hta17430 (<https://doi.org/10.3310%2Fhta17430>). PMC 4781046 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4781046>). PMID 24074752 (<https://pubmed.ncbi.nlm.nih.gov/24074752>).
115. Matthys F, De Backer T, De Backer G, Stichele RV (March 2014). "Review of guidelines on primary prevention of cardiovascular disease with aspirin: how much evidence is needed to turn a tanker?". *European Journal of Preventive Cardiology*. **21** (3): 354–65. doi:10.1177/2047487312472077 (<https://doi.org/10.1177%2F2047487312472077>). PMID 23610452 (<https://pubmed.ncbi.nlm.nih.gov/23610452>).
116. Hodis HN, Mack WJ (July 2014). "Hormone replacement therapy and the association with coronary heart disease and overall mortality: clinical application of the timing hypothesis". *The Journal of Steroid Biochemistry and Molecular Biology*. **142**: 68–75. doi:10.1016/j.jsbmb.2013.06.011 (<https://doi.org/10.1016%2Fj.jsbmb.2013.06.011>). PMID 23851166 (<https://pubmed.ncbi.nlm.nih.gov/23851166>).
117. Anderson L, Taylor RS (December 2014). "Cardiac rehabilitation for people with heart disease: an overview of Cochrane systematic reviews". *The Cochrane Database of Systematic Reviews*. **12** (12): CD011273. doi:10.1002/14651858.CD011273.pub2 (<https://doi.org/10.1002%2F14651858.CD011273.pub2>). hdl:10871/19152 (<https://hdl.handle.net/10871%2F19152>). PMID 25503364 (<https://pubmed.ncbi.nlm.nih.gov/25503364>).
118. Perez MI, Musini VM, Wright JM (October 2009). "Effect of early treatment with anti-hypertensive drugs on short and long-term mortality in patients with an acute cardiovascular event". *The Cochrane Database of Systematic Reviews* (4): CD006743. doi:10.1002/14651858.CD006743.pub2 (<https://doi.org/10.1002%2F14651858.CD006743.pub2>). PMID 19821384 (<https://pubmed.ncbi.nlm.nih.gov/19821384>).
119. Elmariah S, Mauri L, Doros G, Galper BZ, O'Neill KE, Steg PG, et al. (February 2015). "Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4386690>). *Lancet*. **385** (9970): 792–8. doi:10.1016/S0140-6736(14)62052-3 (<https://doi.org/10.1016%2FS0140-6736%2814%2962052-3>). PMC 4386690 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4386690>). PMID 25467565 (<https://pubmed.ncbi.nlm.nih.gov/25467565>).
120. Bangalore S, Makani H, Radford M, Thakur K, Toklu B, Katz SD, et al. (October 2014). "Clinical outcomes with  $\beta$ -blockers for myocardial infarction: a meta-analysis of randomized trials". *The American Journal of Medicine*. **127** (10): 939–53. doi:10.1016/j.amjmed.2014.05.032 (<https://doi.org/10.1016%2Fj.amjmed.2014.05.032>). PMID 24927909 (<https://pubmed.ncbi.nlm.nih.gov/24927909>).

121. Newman, David (19 August 2010). "Beta Blockers for Acute Heart Attack (Myocardial Infarction)" (<http://www.thennnt.com/nnt/beta-blockers-for-heart-attack/>). *TheNNT.com*. Archived (<https://web.archive.org/web/20151222092449/http://www.thennnt.com/nnt/beta-blockers-for-heart-attack/>) from the original on 22 December 2015. Retrieved 11 December 2015.
122. Le HH, El-Khatib C, Mombled M, Guitarian F, Al-Gobari M, Fall M, et al. (2016). "Impact of Aldosterone Antagonists on Sudden Cardiac Death Prevention in Heart Failure and Post-Myocardial Infarction Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4758660>). *PloS One*. **11** (2): e0145958. Bibcode:2016PLoSO..1145958L (<https://ui.adsabs.harvard.edu/abs/2016PLoSO..1145958L>). doi:10.1371/journal.pone.0145958 (<https://doi.org/10.1371%2Fjournal.pone.0145958>). PMC 4758660 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4758660>). PMID 26891235 (<https://pubmed.ncbi.nlm.nih.gov/26891235>).
123. Hazinski MF, Nolan JP, Aickin R, Bhanji F, Billi JE, Callaway CW, et al. (October 2015). "Part 1: Executive Summary: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations". *Circulation* (Review). **132** (16 Suppl 1): S2–39. doi:10.1161/CIR.0000000000000270 (<https://doi.org/10.1161%2FCIR.0000000000000270>). PMID 26472854 (<https://pubmed.ncbi.nlm.nih.gov/26472854>).
124. Papneja K, Chan AK, Mondal TK, Paes B (March 2017). "Myocardial Infarction in Neonates: A Review of an Entity with Significant Morbidity and Mortality". *Pediatric Cardiology*. **38** (3): 427–441. doi:10.1007/s00246-016-1556-7 (<https://doi.org/10.1007%2Fs00246-016-1556-7>). PMID 28238152 (<https://pubmed.ncbi.nlm.nih.gov/28238152>).
125. López de Sá E, López-Sendón J, Anguera I, Bethencourt A, Bosch X (November 2002). "Prognostic value of clinical variables at presentation in patients with non-ST-segment elevation acute coronary syndromes: results of the Proyecto de Estudio del Pronóstico de la Angina (PEPA)". *Medicine*. **81** (6): 434–42. doi:10.1097/00005792-200211000-00004 (<https://doi.org/10.1097%2F00005792-200211000-00004>). PMID 12441900 (<https://pubmed.ncbi.nlm.nih.gov/12441900>).
126. Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, et al. (November 2006). "Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE)" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1661748>). *BMJ*. **333** (7578): 1091. doi:10.1136/bmj.38985.646481.55 (<https://doi.org/10.1136%2Fbmj.38985.646481.55>). PMC 1661748 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1661748>). PMID 17032691 (<https://pubmed.ncbi.nlm.nih.gov/17032691>).
127. Weir RA, McMurray JJ, Velazquez EJ (May 2006). "Epidemiology of heart failure and left ventricular systolic dysfunction after acute myocardial infarction: prevalence, clinical characteristics, and prognostic importance". *The American Journal of Cardiology*. **97** (10A): 13F–25F. doi:10.1016/j.amjcard.2006.03.005 (<https://doi.org/10.1016%2Fj.amjcard.2006.03.005>). PMID 16698331 (<https://pubmed.ncbi.nlm.nih.gov/16698331>).
128. World Health Organization (2008). *The Global Burden of Disease: 2004 Update*. Geneva: World Health Organization. ISBN 978-92-4-156371-0.
129. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. (American Heart Association Statistics Committee and Stroke Statistics Subcommittee) (January 2012). "Executive summary: heart disease and stroke statistics--2012 update: a report from the American Heart Association". *Circulation*. **125** (1): 188–97. doi:10.1161/CIR.0b013e3182456d46 (<https://doi.org/10.1161%2FCIR.0b013e3182456d46>). PMID 22215894 (<https://pubmed.ncbi.nlm.nih.gov/22215894>).

130. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. (January 2015). "Heart disease and stroke statistics--2015 update: a report from the American Heart Association". *Circulation*. **131** (4): e29–322. doi:10.1161/cir.0000000000000152 (<https://doi.org/10.1161%2Fcir.0000000000000152>). PMID 25520374 (<https://pubmed.ncbi.nlm.nih.gov/25520374/>). "From 2001 to 2011, death rates attributable to CVD declined 30.8%."
131. Gupta R, Joshi P, Mohan V, Reddy KS, Yusuf S (January 2008). "Epidemiology and causation of coronary heart disease and stroke in India". *Heart*. **94** (1): 16–26. doi:10.1136/hrt.2007.132951 (<https://doi.org/10.1136%2Fhrt.2007.132951>). PMID 18083949 (<https://pubmed.ncbi.nlm.nih.gov/18083949/>).
132. Perry K, Petrie KJ, Ellis CJ, Horne R, Moss-Morris R (July 2001). "Symptom expectations and delay in acute myocardial infarction patients" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1729795>). *Heart*. **86** (1): 91–3. doi:10.1136/heart.86.1.91 (<https://doi.org/10.1136%2Fheart.86.1.91>). PMC 1729795 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1729795>). PMID 11410572 (<https://pubmed.ncbi.nlm.nih.gov/11410572/>).
133. Workers' Compensation FAQ (<http://www.pvamu.edu/pages/2026.asp>) Archived (<https://web.archive.org/web/20070711235600/http://www.pvamu.edu/pages/2026.asp>) 2007-07-11 at the Wayback Machine. Prairie View A&M University. Retrieved November 22, 2006.
134. SIGNIFICANT DECISIONS Subject Index (<http://www.biia.wa.gov/significantdecisions/contents.htm>) Archived ([https://web.archive.org/web/20061206115257/http://www.biia.wa.gov/Sig nificantDecisions/contents.htm](https://web.archive.org/web/20061206115257/http://www.biia.wa.gov/Sig%20nificantDecisions/contents.htm)) 2006-12-06 at the Wayback Machine. Board of Industrial Insurance Appeals. Retrieved November 22, 2006.
135. "Classification of Drivers' Licenses Regulations" (<http://www.gov.ns.ca/just/regulations/regs/mvclasdl.htm>). Nova Scotia Registry of Regulations. May 24, 2000. Archived (<https://web.archive.org/web/20070420191108/http://www.gov.ns.ca/just/regulations/regs/mvclasdl.htm>) from the original on April 20, 2007. Retrieved April 22, 2007.

## Further reading

- Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. (March 2016). "2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Society for Cardiovascular Angiography and Interventions". *Circulation*. **133** (11): 1135–47. doi:10.1161/CIR.0000000000000336 (<https://doi.org/10.1161%2FCIR.0000000000000336>). PMID 26490017 (<https://pubmed.ncbi.nlm.nih.gov/26490017/>).

## External links

- Myocardial infarction ([https://curlie.org/Health/Conditions\\_and\\_Diseases/Cardiovascular\\_Disorders/Heart\\_Disease](https://curlie.org/Health/Conditions_and_Diseases/Cardiovascular_Disorders/Heart_Disease)) at Curlie
- American Heart Association's Heart Attack web site (<http://www.americanheart.org/heartattack>) — Information and resources for preventing, recognizing and treating a heart attack.
- TIMI Score for UA/NSTEMI (<http://www.mdcalc.com/timi-risk-score-for-uanstemi/>) and STEMI (<http://www.mdcalc.com/timi-risk-score-for-stemi/>)
- HEART Score for Major Cardiac Events (<http://www.mdcalc.com/heart-score-for-major-cardiac-events/>)

**Classification** **ICD-10:** I21 (<http://apps.who.int/classifications/icd10/browse/2016/en#/I21>)-I22 (<http://apps.who.int/classifications/icd10/browse/2016/en#/I22>) · **ICD-9-CM:** 410 (<http://www.icd9data.com/getICD9>)

	<p>Code.ashx?icd9=410) • <b>MeSH:</b>  D009203 (<a href="https://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&amp;term=D009203">https://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&amp;term=D009203</a>) •</p> <p><b>DiseasesDB:</b> 8664 (<a href="http://www.diseasesdatabase.com/ddb8664.htm">http://www.diseasesdatabase.com/ddb8664.htm</a>)</p>
<b>External resources</b>	<p><b>MedlinePlus:</b>  000195 (<a href="https://www.nlm.nih.gov/medlineplus/ency/article/000195.htm">https://www.nlm.nih.gov/medlineplus/ency/article/000195.htm</a>) •</p> <p><b>eMedicine:</b>  med/1567 (<a href="https://emedicine.medscape.com/med/1567-overview/emerg/327">https://emedicine.medscape.com/med/1567-overview/emerg/327</a>) (<a href="http://www.emedicine.com/emerg/topic327.htm#">http://www.emedicine.com/emerg/topic327.htm#</a>) ped/2520 (<a href="http://www.emedicine.com/ped/topic2520.htm#">http://www.emedicine.com/ped/topic2520.htm#</a>) • <b>Patient UK:</b> Myocardial infarction (<a href="https://patient.info/doctor/acute-myocardial-infarction">https://patient.info/doctor/acute-myocardial-infarction</a>)</p>

---

Retrieved from "[https://en.wikipedia.org/w/index.php?title=Myocardial\\_infarction&oldid=934639757](https://en.wikipedia.org/w/index.php?title=Myocardial_infarction&oldid=934639757)"

---

**This page was last edited on 7 January 2020, at 17:15 (UTC).**

Text is available under the [Creative Commons Attribution-ShareAlike License](#); additional terms may apply. By using this site, you agree to the [Terms of Use](#) and [Privacy Policy](#). Wikipedia® is a registered trademark of the [Wikimedia Foundation, Inc.](#), a non-profit organization.